Skip to main content
Psychedex
Sources
25
1 strong · 13 moderate · 11 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
114
73verified12partial29inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 8, 2026 · pipeline-v5
Values approved
97/97 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

insufflatedtrace

FieldPublishedAI ProposedConfidence
Threshold5 mg5 mglow
Low5–15 mg5–15 mglow
Common15–25 mg15–25 mglow
Strong25–40 mg25–40 mglow
Heavy40+ mg40+ mglow
Editorial

Common range (15–25 mg) from De la Rosa 2025 human observational study — only tier with published human data (confidence medium for that tier alone). Threshold (~5 mg), light (5–15 mg), strong (25–40 mg), and heavy (>40 mg) extrapolated from position relative to the published common range and structural analogy to α-PVP/α-PHP dose ranges. All tiers except common are low confidence.

Reasoning

Common range (15–25 mg) from De la Rosa 2025 human observational study — only tier with published human data (confidence medium for that tier alone). Threshold (~5 mg), light (5–15 mg), strong (25–40 mg), and heavy (>40 mg) extrapolated from position relative to the published common range and structural analogy to α-PVP/α-PHP dose ranges. All tiers except common are low confidence.

Evidence basis: published_case_series

smokedtrace

FieldPublishedAI ProposedConfidence
Threshold3 mg3 mglow
Low3–10 mg3–10 mglow
Common10–20 mg10–20 mglow
Strong20–30 mg20–30 mglow
Heavy30+ mg30+ mglow
Editorial

All values from community sources (PsychonautWiki talk page, unverified). No published clinical or observational data for vaporized/smoked route. Lower doses than insufflated consistent with higher bioavailability via pulmonary absorption.

Reasoning

All values from community sources (PsychonautWiki talk page, unverified). No published clinical or observational data for vaporized/smoked route. Lower doses than insufflated consistent with higher bioavailability via pulmonary absorption.

Evidence basis: community_consensus_small

Duration

insufflated

FieldPublishedAI ProposedConfidence
Onsettrace5–20 minutes5–20 minutesmedium
Editorial

T_max ~20 min from De la Rosa 2025 human observational study (oral fluid); onset precedes peak, so first effects estimated at 5 min with peak at ~20 min.

Reasoning

T_max ~20 min from De la Rosa 2025 human observational study (oral fluid); onset precedes peak, so first effects estimated at 5 min with peak at ~20 min.

Evidence basis: published_case_series

Come uptrace5–15 minutes5–15 minuteslow
Editorial

Inferred gap between first effects and peak; derived from T_max data in De la Rosa 2025 and pharmacokinetic reasoning.

Reasoning

Inferred gap between first effects and peak; derived from T_max data in De la Rosa 2025 and pharmacokinetic reasoning.

Evidence basis: published_case_series

Peaktrace30–60 minutes30–60 minutesmedium
Editorial

PK-derived from T_max (~20 min) and half-life (~1.1 h) from De la Rosa 2025. Peak intensity window estimated at 30–60 min.

Reasoning

PK-derived from T_max (~20 min) and half-life (~1.1 h) from De la Rosa 2025. Peak intensity window estimated at 30–60 min.

Evidence basis: published_case_series

Offsettrace60–120 minutes60–120 minuteslow
Editorial

Inferred from plasma half-life of ~1.1 h (De la Rosa 2025). Offset represents declining effects after peak through return to near-baseline.

Reasoning

Inferred from plasma half-life of ~1.1 h (De la Rosa 2025). Offset represents declining effects after peak through return to near-baseline.

Evidence basis: published_case_series

Totaltrace2–4 hours2–4 hoursmedium
Editorial

PK-derived estimate from De la Rosa 2025 pharmacokinetic parameters (T_max ~20 min, half-life ~1.1 h). Total subjective experience estimated at 2–4 hours.

Reasoning

PK-derived estimate from De la Rosa 2025 pharmacokinetic parameters (T_max ~20 min, half-life ~1.1 h). Total subjective experience estimated at 2–4 hours.

Evidence basis: published_case_series

After effectstrace2–6 hours2–6 hourslow
Editorial

No published data on aftereffects duration. Estimated from stimulant class analogy — residual wakefulness, insomnia, and mild dysphoria expected for several hours after subjective offset.

Reasoning

No published data on aftereffects duration. Estimated from stimulant class analogy — residual wakefulness, insomnia, and mild dysphoria expected for several hours after subjective offset.

Evidence basis: structural_analogy

smoked

FieldPublishedAI ProposedConfidence
Onsettrace0.5–1 minutes0.5–1 minuteslow
Editorial

Community reports (PsychonautWiki) indicate near-instantaneous onset via vaporized route, consistent with pulmonary absorption pharmacokinetics.

Reasoning

Community reports (PsychonautWiki) indicate near-instantaneous onset via vaporized route, consistent with pulmonary absorption pharmacokinetics.

Evidence basis: community_consensus_small

Peaktrace15–45 minutes15–45 minuteslow
Editorial

Community reports (PsychonautWiki). Shorter peak than insufflated consistent with faster absorption and redistribution kinetics.

Reasoning

Community reports (PsychonautWiki). Shorter peak than insufflated consistent with faster absorption and redistribution kinetics.

Evidence basis: community_consensus_small

Offsettrace30–90 minutes30–90 minuteslow
Editorial

Community reports (PsychonautWiki). Rapid decline consistent with high peak followed by redistribution.

Reasoning

Community reports (PsychonautWiki). Rapid decline consistent with high peak followed by redistribution.

Evidence basis: community_consensus_small

Totaltrace1–3 hours1–3 hourslow
Editorial

Community reports (PsychonautWiki). Shorter total duration than insufflated consistent with faster absorption/redistribution via pulmonary route.

Reasoning

Community reports (PsychonautWiki). Shorter total duration than insufflated consistent with faster absorption/redistribution via pulmonary route.

Evidence basis: community_consensus_small

After effectstrace6–12 hours6–12 hourslow
Editorial

Community reports (PsychonautWiki). Extended aftereffects relative to subjective duration consistent with stimulant class pattern of residual insomnia and dysphoria.

Reasoning

Community reports (PsychonautWiki). Extended aftereffects relative to subjective duration consistent with stimulant class pattern of residual insomnia and dysphoria.

Evidence basis: community_consensus_small

oral

FieldPublishedAI ProposedConfidence
Onsettrace30–60 minutes30–60 minuteslow
Editorial

Dinis 2024 review states oral onset is 30–60 min for α-PiHP, though the primary source for this claim is not cited. Treat as provisional.

Reasoning

Dinis 2024 review states oral onset is 30–60 min for α-PiHP, though the primary source for this claim is not cited. Treat as provisional.

Evidence basis: expert_opinion

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutehighhighmedium
Chronicmoderatemoderatemedium
Organs Affectedcardiovascular, renal, thermoregulatory, neuropsychiatriccardiovascular, renal, thermoregulatory, neuropsychiatricmedium
Editorial

Acute rated 'high' based on multiple independent fatal case series and documented life-threatening hyperthermia/cardiac arrest, but not 'critical' because single-substance lethality attribution is limited (nearly all fatal cases are polydrug). Chronic rated 'moderate' via class inference from α-PVP/MDPV literature — no α-PiHP-specific chronic toxicity data exist, so discounted one level from the 'high' that raw class findings might suggest.

Reasoning

Acute rated 'high' based on multiple independent fatal case series and documented life-threatening hyperthermia/cardiac arrest, but not 'critical' because single-substance lethality attribution is limited (nearly all fatal cases are polydrug). Chronic rated 'moderate' via class inference from α-PVP/MDPV literature — no α-PiHP-specific chronic toxicity data exist, so discounted one level from the 'high' that raw class findings might suggest.

Evidence basis: published_case_series

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalnegligiblenegligiblelow
Psychologicalhighhighlow
Compulsive Redosinghighhighlow
Dose Escalationhighhighlow
Editorial

All dependence characteristics are class-level inferences from α-PVP, MDPV, and pyrovalerone literature (Weinstein 2017, Daziani 2023). WHO ECDD assessed α-PiHP as having high abuse potential based on animal models. No α-PiHP-specific dependence or withdrawal studies exist. Confidence is low due to complete reliance on structural analogy.

Reasoning

All dependence characteristics are class-level inferences from α-PVP, MDPV, and pyrovalerone literature (Weinstein 2017, Daziani 2023). WHO ECDD assessed α-PiHP as having high abuse potential based on animal models. No α-PiHP-specific dependence or withdrawal studies exist. Confidence is low due to complete reliance on structural analogy.

Evidence basis: structural_analogy

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitymoderatemoderatelow
Symptomscravings, anhedonia, fatigue, dysphoria, depression, anxietycravings, anhedonia, fatigue, dysphoria, depression, anxietylow
FatalNoNolow
Medical SupervisionNot requiredNot requiredlow
Editorial

Withdrawal is psychological only — no physical dependence syndrome described for pyrovalerone cathinones. Symptoms, onset, and duration inferred from stimulant class (α-PVP, MDPV, cocaine withdrawal patterns). Severity rated moderate based on class inference; discounted from 'severe' given no α-PiHP-specific data.

Reasoning

Withdrawal is psychological only — no physical dependence syndrome described for pyrovalerone cathinones. Symptoms, onset, and duration inferred from stimulant class (α-PVP, MDPV, cocaine withdrawal patterns). Severity rated moderate based on class inference; discounted from 'severe' given no α-PiHP-specific data.

Evidence basis: structural_analogy

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Builduprapidrapidlow
Half-life2 days2 dayslow
Full Reset5 days5 dayslow
Cross-tolerancesα-PVP, α-PHP, MDPV, other pyrovalerone cathinones, cocaine (partial), amphetamines (partial)α-PVP, α-PHP, MDPV, other pyrovalerone cathinones, cocaine (partial), amphetamines (partial)low
Editorial

All tolerance parameters inferred from α-PVP, MDPV, and general stimulant class literature (Weinstein 2017). No α-PiHP-specific tolerance studies published. Rapid buildup during binge use is a consistent finding across pyrovalerone cathinones. Half-life and reset values are estimates based on stimulant class analogs.

Reasoning

All tolerance parameters inferred from α-PVP, MDPV, and general stimulant class literature (Weinstein 2017). No α-PiHP-specific tolerance studies published. Rapid buildup during binge use is a consistent finding across pyrovalerone cathinones. Half-life and reset values are estimates based on stimulant class analogs.

Evidence basis: structural_analogy

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
renal Renal impairmenttracerelativerelativemedium
Editorial

Rhabdomyolysis and AKI documented in T'kind 2024 case report (5g oral ingestion). Direct clinical evidence, though from a single extreme-dose case.

Reasoning

Rhabdomyolysis and AKI documented in T'kind 2024 case report (5g oral ingestion). Direct clinical evidence, though from a single extreme-dose case.

pregnancy breastfeeding Pregnancy and lactationtraceabsoluteabsolutelow
Editorial

No direct data. Class-level contraindication based on established sympathomimetic stimulant risks to fetal development.

Reasoning

No direct data. Class-level contraindication based on established sympathomimetic stimulant risks to fetal development.

cardiovascular Cardiovascular diseasetraceabsoluteabsolutemedium
Editorial

Tachycardia and sustained hypertension documented in human observational study (De la Rosa 2025); sudden cardiac arrest in fatal cases (Skowronek 2025, Kriikku 2024). Direct evidence from multiple independent sources.

Reasoning

Tachycardia and sustained hypertension documented in human observational study (De la Rosa 2025); sudden cardiac arrest in fatal cases (Skowronek 2025, Kriikku 2024). Direct evidence from multiple independent sources.

psychiatric Psychotic spectrum disorderstraceabsoluteabsolutemedium
Editorial

Hallucinations, delusions, and paranoia documented in intoxication cases (Dinis 2024, ECDD repository). Dopaminergic mechanism directly exacerbates psychotic vulnerability.

Reasoning

Hallucinations, delusions, and paranoia documented in intoxication cases (Dinis 2024, ECDD repository). Dopaminergic mechanism directly exacerbates psychotic vulnerability.

psychiatric Bipolar disordertraceabsoluteabsolutelow
Editorial

Class-level inference from stimulant pharmacology. No α-PiHP-specific bipolar case data, but mechanism-based risk is established.

Reasoning

Class-level inference from stimulant pharmacology. No α-PiHP-specific bipolar case data, but mechanism-based risk is established.

neurological Seizure disorderstracerelativerelativelow
Editorial

Class-level inference from sympathomimetic stimulant pharmacology. No direct α-PiHP seizure reports identified, but the mechanism-based risk is established.

Reasoning

Class-level inference from sympathomimetic stimulant pharmacology. No direct α-PiHP seizure reports identified, but the mechanism-based risk is established.

other MAO inhibitor therapytraceabsoluteabsolutemedium
Editorial

Mechanism-based contraindication: blocked degradation + blocked reuptake → excessive monoamine accumulation. No published case reports of this specific combination, but the pharmacological basis is well established.

Reasoning

Mechanism-based contraindication: blocked degradation + blocked reuptake → excessive monoamine accumulation. No published case reports of this specific combination, but the pharmacological basis is well established.

psychiatric Severe anxiety disorderstracerelativerelativelow
Editorial

Anxiety and paranoia documented in case reports (Dinis 2024, Daziani 2023). Class inference from stimulant pharmacology.

Reasoning

Anxiety and paranoia documented in case reports (Dinis 2024, Daziani 2023). Class inference from stimulant pharmacology.

metabolic Hyperthyroidismtracerelativerelativelow
Editorial

Class-level contraindication inherited from cathinone/pyrovalerone/sympathomimetic stimulant class. No α-PiHP-specific data.

Reasoning

Class-level contraindication inherited from cathinone/pyrovalerone/sympathomimetic stimulant class. No α-PiHP-specific data.

Timeline Phases

insufflated

FieldPublishedAI ProposedConfidence
Onsettrace0–300 sec(i=0.15)0–300 sec(i=0.15)medium
Editorial

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Reasoning

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Evidence basis: published_case_series

Come uptrace300–900 sec(i=0.50)300–900 sec(i=0.50)medium
Editorial

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Reasoning

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Evidence basis: published_case_series

Peaktrace1800–3600 sec(i=1.00)1800–3600 sec(i=1.00)medium
Editorial

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Reasoning

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Evidence basis: published_case_series

Resolutiontrace3600–7200 sec(i=0.40)3600–7200 sec(i=0.40)medium
Editorial

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Reasoning

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Evidence basis: published_case_series

Afterglowtrace10800–28800 sec(i=0.15)10800–28800 sec(i=0.15)medium
Editorial

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Reasoning

Insufflated timeline derived from De la Rosa 2025 human PK data (T_max ~20 min, half-life ~1.1 h). Onset and come_up phases based on T_max. Peak duration PK-derived. Resolution and afterglow inferred from half-life and stimulant class patterns. Confidence medium for onset/peak (published PK), low for resolution/afterglow (class inference).

Evidence basis: published_case_series

smoked

FieldPublishedAI ProposedConfidence
Onsettrace0–60 sec(i=0.80)0–60 sec(i=0.80)low
Editorial

Smoked/vaporized timeline from community reports (PsychonautWiki, unverified). No published clinical data for this route. Phase structure simplified (no separate come_up) to match the near-instantaneous onset characteristic of vaporized pyrovalerone cathinones. Extended afterglow relative to brief peak is consistent with stimulant class patterns.

Reasoning

Smoked/vaporized timeline from community reports (PsychonautWiki, unverified). No published clinical data for this route. Phase structure simplified (no separate come_up) to match the near-instantaneous onset characteristic of vaporized pyrovalerone cathinones. Extended afterglow relative to brief peak is consistent with stimulant class patterns.

Evidence basis: community_consensus_small

Peaktrace60–1800 sec(i=1.00)60–1800 sec(i=1.00)low
Editorial

Smoked/vaporized timeline from community reports (PsychonautWiki, unverified). No published clinical data for this route. Phase structure simplified (no separate come_up) to match the near-instantaneous onset characteristic of vaporized pyrovalerone cathinones. Extended afterglow relative to brief peak is consistent with stimulant class patterns.

Reasoning

Smoked/vaporized timeline from community reports (PsychonautWiki, unverified). No published clinical data for this route. Phase structure simplified (no separate come_up) to match the near-instantaneous onset characteristic of vaporized pyrovalerone cathinones. Extended afterglow relative to brief peak is consistent with stimulant class patterns.

Evidence basis: community_consensus_small

Resolutiontrace1800–7200 sec(i=0.30)1800–7200 sec(i=0.30)low
Editorial

Smoked/vaporized timeline from community reports (PsychonautWiki, unverified). No published clinical data for this route. Phase structure simplified (no separate come_up) to match the near-instantaneous onset characteristic of vaporized pyrovalerone cathinones. Extended afterglow relative to brief peak is consistent with stimulant class patterns.

Reasoning

Smoked/vaporized timeline from community reports (PsychonautWiki, unverified). No published clinical data for this route. Phase structure simplified (no separate come_up) to match the near-instantaneous onset characteristic of vaporized pyrovalerone cathinones. Extended afterglow relative to brief peak is consistent with stimulant class patterns.

Evidence basis: community_consensus_small

Afterglowtrace7200–43200 sec(i=0.15)7200–43200 sec(i=0.15)low
Editorial

Smoked/vaporized timeline from community reports (PsychonautWiki, unverified). No published clinical data for this route. Phase structure simplified (no separate come_up) to match the near-instantaneous onset characteristic of vaporized pyrovalerone cathinones. Extended afterglow relative to brief peak is consistent with stimulant class patterns.

Reasoning

Smoked/vaporized timeline from community reports (PsychonautWiki, unverified). No published clinical data for this route. Phase structure simplified (no separate come_up) to match the near-instantaneous onset characteristic of vaporized pyrovalerone cathinones. Extended afterglow relative to brief peak is consistent with stimulant class patterns.

Evidence basis: community_consensus_small

Dose Tier Summaries

thresholdtrace
low

Sub-perceptual stimulation registers as a slight increase in alertness and a faint uplift in mood without clear euphoria. The experience is barely distinguishable from placebo in users without prior cathinone exposure. Physical signs are minimal — a subtle increase in heart rate may be noticed by attentive users. Appetite suppression is absent or negligible. Sleep is not significantly disrupted if administered early in the day. No compulsive redosing urge is expected at this level. The threshold varies by route: vaporized administration may produce noticeable effects at doses that remain sub-threshold via insufflation or oral ingestion.

Editorial

No published threshold data for α-PiHP. Estimated at ~5 mg insufflated based on position below the light range in user reports. Route-dependent variation inferred from pharmacokinetic differences (near-instantaneous vaporized onset vs. 20 min insufflated).

Reasoning

No published threshold data for α-PiHP. Estimated at ~5 mg insufflated based on position below the light range in user reports. Route-dependent variation inferred from pharmacokinetic differences (near-instantaneous vaporized onset vs. 20 min insufflated).

Evidence basis: structural_analogy

lighttrace
low

Noticeable stimulation emerges with mild euphoria, increased focus, and sustained wakefulness. Thought acceleration becomes apparent — mental activity feels quicker and more fluid. Mood elevation is present but moderate, without the intense rush characteristic of higher doses. Physically, appetite suppression begins, heart rate increases modestly, and a subtle body high may be felt as increased energy and bodily lightness. Cardiovascular effects are present but not pronounced. Sleep will be delayed for 2–4 hours after effects subside. The compulsive redosing urge is minimal at this tier but may emerge as effects begin to fade, particularly with vaporized administration where the rapid offset creates a sharper contrast.

Editorial

Insufflated light range (5–15 mg) inferred from the lower bound of the De la Rosa 2025 study range. Effects extrapolated from α-PVP/α-PHP class profile with adjustment for α-PiHP's lower CNS bioavailability.

Reasoning

Insufflated light range (5–15 mg) inferred from the lower bound of the De la Rosa 2025 study range. Effects extrapolated from α-PVP/α-PHP class profile with adjustment for α-PiHP's lower CNS bioavailability.

Evidence basis: structural_analogy

commontrace
medium

Clear stimulant effects dominate — pronounced cognitive euphoria, marked wakefulness, and appetite suppression. Focus enhancement and motivation enhancement are prominent. Thought acceleration is obvious, and users may experience increased sociability, though without the empathogenic warmth of serotonergic stimulants due to α-PiHP's negligible SERT activity. Physically, heart rate and blood pressure are noticeably elevated — blood pressure elevation is more sustained than with comparable cocaine doses. Excessive sweating, dry mouth, and mild bruxism may occur. Restlessness becomes apparent. Pupil dilation is likely. The compulsive redosing urge emerges at this tier and can intensify as peak effects begin to fade. This is the range studied in the De la Rosa 2025 human observational study (15–25 mg insufflated). Sleep will be impossible for several hours.

Editorial

Common insufflated range (15–25 mg) directly from De la Rosa 2025 observational study. Subjective and cardiovascular effects described in that study: stimulant profile similar to cocaine, more sustained blood pressure elevation. DAT-selective profile explains absence of empathogenic character.

Reasoning

Common insufflated range (15–25 mg) directly from De la Rosa 2025 observational study. Subjective and cardiovascular effects described in that study: stimulant profile similar to cocaine, more sustained blood pressure elevation. DAT-selective profile explains absence of empathogenic character.

Evidence basis: published_case_series

strongtrace
low

Intense stimulation with significant cardiovascular load. Euphoria is pronounced but accompanied by emerging anxiety and paranoia as noradrenergic activation escalates. Psychomotor agitation replaces purposeful energy — restlessness becomes uncomfortable rather than motivating. Thought acceleration may become thought disorganization at the upper end of this range. Cardiovascular stress is substantial: marked tachycardia, sustained hypertension, and vasoconstriction. Temperature dysregulation begins — excessive sweating and heat intolerance. Muscle tension and bruxism intensify. Insomnia will persist for many hours. The compulsive redosing urge is strong and represents a primary risk at this tier. The urge to redose persists even as subjective pleasure plateaus, driven by α-PiHP's selective dopaminergic reinforcement mechanism. Each redose compounds cardiovascular risk.

Editorial

Extrapolated above the De la Rosa 2025 common range (25–40 mg insufflated). Cardiovascular escalation and anxiety/paranoia emergence inferred from case reports and the sympathomimetic toxidrome documented across pyrovalerone cathinones. Compulsive redosing pattern from class-level behavioral evidence (Weinstein 2017).

Reasoning

Extrapolated above the De la Rosa 2025 common range (25–40 mg insufflated). Cardiovascular escalation and anxiety/paranoia emergence inferred from case reports and the sympathomimetic toxidrome documented across pyrovalerone cathinones. Compulsive redosing pattern from class-level behavioral evidence (Weinstein 2017).

Evidence basis: structural_analogy

heavytrace
low

Overstimulation with serious cardiovascular risk. Euphoria may be entirely replaced by dysphoria, anxiety, and paranoia. At the upper end, psychotic features can emerge — auditory and visual hallucinations, persecutory delusions, and agitated delirium. Confusion and decision impairment are likely. Reality testing may be severely compromised. Cardiovascular danger is acute: risk of cardiac arrhythmias, hypertensive emergency, and life-threatening hyperthermia with secondary rhabdomyolysis and acute kidney injury. Trembling, involuntary body movements, and severe psychomotor agitation may occur. Emergency medical intervention may be needed. This tier carries the highest risk of excited delirium syndrome — extreme agitation, hyperthermia, and loss of pain sensitivity — a recognized cause of death in pyrovalerone cathinone intoxication. Route matters: the oral route's delayed onset (30–60 minutes) creates specific overdose risk from premature redosing before effects manifest.

Editorial

Extrapolated from case reports of severe intoxication (T'kind 2024 — 5g oral with hyperthermia and rhabdomyolysis) and fatal case series (Wachholz 2023, Kriikku 2024, Skowronek 2025). Psychotic features documented in ECDD repository and Dinis 2024 review. Excited delirium from pyrovalerone class literature (Penders 2012).

Reasoning

Extrapolated from case reports of severe intoxication (T'kind 2024 — 5g oral with hyperthermia and rhabdomyolysis) and fatal case series (Wachholz 2023, Kriikku 2024, Skowronek 2025). Psychotic features documented in ECDD repository and Dinis 2024 review. Excited delirium from pyrovalerone class literature (Penders 2012).

Evidence basis: structural_analogy

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

1 strong · 13 moderate · 11 weak
  1. [1]
    moderate
    α-Pyrrolidinohexanophenone (α-PHP) and α-Pyrrolidinoisohexanophenone (α-PiHP): A Review
    Dinis P, Franco J, Margalho C · 2024 · Life
    doi.org/10.3390/life14040429pubmed 3867270112 claims checked7 verified1 partial4 inconclusive
  2. [2]
    moderate
    The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative.
    Kolaczynska KE, Thomann J, Hoener MC, Liechti ME · 2021 · International journal of molecular sciences
    doi.org/10.3390/ijms22158277pubmed 343610407 claims checked4 verified2 partial1 inconclusive
  3. [3]
    moderate
    A review of synthetic cathinones emerging in recent years (2019–2022).
    Kuropka P, Zawadzki M, Szpot P · 2022 · Forensic Toxicology
    doi.org/10.1007/s11419-022-00639-5pubmed 361241072 claims checked1 partial1 inconclusive
  4. [4]
    moderate
    Pharmacological effects and pharmacokinetics of the novel synthetic cathinone α-pyrrolidinoisohexanophenone (α-PiHP) compared with α-pyrrolidinovalerophenone (α-PVP) in mice
    Baarset AM, Steinsland S, Nerem E, Andersen JM, Baumann MH, Bogen IL · 2025 · Neurotoxicology
    doi.org/10.1016/j.neuro.2025.05.005pubmed 403818099 claims checked9 verified
  5. [5]
    weak
    WHO Expert Committee on Drug Dependence Forty-Fifth Report: recommendation on alpha-PiHP
    World Health Organization Expert Committee on Drug Dependence · 2022
    linkno claims checked
  6. [6]
    moderate
    Synthetic Cathinone and Cannabinoid Designer Drugs Pose a Major Risk for Public Health
    Weinstein A, Rosca P, Fattore L, London ED · 2017 · Frontiers in Psychiatry
    doi.org/10.3389/fpsyt.2017.00156pubmed 288786986 claims checked1 verified5 inconclusive
  7. [7]
    moderate
    In vitro monoamine reuptake inhibition and forensic case series in Sweden of the synthetic cathinones 2-, 3-, and 4-Me-alpha-PiHP
    Gréen H, Persson M, Wikström M, Monti MC · 2025 · Forensic Science International
    doi.org/10.1016/j.forsciint.2025.112657pubmed 409922549 claims checked5 verified4 inconclusive
  8. [8]
    weak
    Case series involving the synthetic cathinones alpha-PHP, alpha-PiHP, MDPHP, and MDPiHP in forensic investigations
    Gomonit MM, Walton SE, Papsun DM, Lamb ME, Chronister CW, et al. · 2026 · Forensic Science International
    doi.org/10.1016/j.forsciint.2026.112917pubmed 418307776 claims checked6 verified
  9. [9]
    moderate
    Disposition and effects of alpha-pyrrolidinoisohexanophenone (α-PHiP) in comparison with cocaine: an observational study
    De la Rosa G, Iacobone G, Papaseit E, Hladun O, Poyatos L, Caicedo DA, Argote MC, Martín S, Ventura M, Di Giorgi A, Graziano S, Pichini S, Marchei E, Farré M, Pérez-Mañá C · 2025 · Frontiers in Pharmacology
    doi.org/10.3389/fphar.2025.1728824pubmed 4161407112 claims checked7 verified4 partial1 inconclusive
  10. [10]
    weak
    Use of psychoactive substances among hard coal miners during work – a case report of fatal α-PiHP and tramadol poisoning
    Skowronek R, Wachholz P, Bujak-Giżycka B, Celiński R, Pawlas N · 2025 · Problems of Forensic Sciences
    doi.org/10.4467/12307483pfs.25.010.229177 claims checked7 verified
  11. [11]
    moderate
    Metabolism of the Synthetic Cathinone Alpha-Pyrrolidinoisohexanophenone in Humans Using UHPLC-MS-QToF
    Kemenes K, Hidvegi E, Szabo L, Kerner A, Suvegh G · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkac085pubmed 362870604 claims checked2 verified1 partial1 inconclusive
  12. [12]
    weak
    Management of Suspected α-Pyrrolidinoisohexanophenone (α-PiHP)-Related Hyperthermia in a Young Adult: A Case Report
    T'kind T, Vialatte PB, Roger C, Saadi L, Muller L · 2024 · Cureus
    doi.org/10.7759/cureus.70708pubmed 394930376 claims checked6 verified
  13. [13]
    weak
    Synthetic cathinones: an updated harms assessment (ACMD)
    Advisory Council on the Misuse of Drugs (UK) · 2025
    linkno claims checked
  14. [14]
    weak
    Specific Listing for Three Currently Controlled Schedule I Substances (includes alpha-PiHP)
    US Drug Enforcement Administration · 2023
    linkno claims checked
  15. [15]
    moderate
    In vitro metabolic studies and machine learning analysis of mass spectrometry data: A dual strategy for differentiating alpha-pyrrolidinohexiophenone (α-PHP) and alpha-pyrrolidinoisohexanophenone (α-PiHP) in urine analysis
    Yeh YL, Wen CY, Hsieh CL, Chang YH, Wang SM · 2024 · Forensic Science International
    doi.org/10.1016/j.forsciint.2024.112134pubmed 389965405 claims checked1 verified2 partial2 inconclusive
  16. [16]
    weak
    A case of intoxication with a new cathinone derivative α-PiHP - A presentation of concentrations in biological specimens
    Adamowicz P, Jurczyk A, Gil D, Szustowski S · 2020 · Legal Medicine (Tokyo, Japan)
    doi.org/10.1016/j.legalmed.2019.101626pubmed 317517961 claim checked1 inconclusive
  17. [17]
    weak
    A fatal case of poisoning with a cathinone derivative: α-PiHP and its postmortem distribution in body fluids and organ tissues
    Wachholz P, Celinski R, Bujak-Gizycka B, Skowronek R, Pawlas N · 2023 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkad026pubmed 371300494 claims checked4 verified
  18. [18]
    weak
    α-PiHP UNODC Substance Details
    UNODC Laboratory and Scientific Service · 2023
    linkno claims checked
  19. [19]
    weak
    ECDD Repository: Alpha-PiHP Entry
    WHO Expert Committee on Drug Dependence Repository · 2022
    linkno claims checked
  20. [20]
    moderate
    α-Pyrrolidinohexanophenone (α-PHP) vs. α-pyrrolidinoisohexanophenone (α-PiHP): A toxicological investigation about plasma concentrations and behavior in forensic routine cases
    Brueckner I, Welter J, Zangl A, Graw M, Paul LD · 2024 · Journal of Analytical Toxicology
    doi.org/10.1093/jat/bkae011pubmed 384919876 claims checked4 verified2 inconclusive
  21. [21]
    strong
    Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review
    Daziani G, Lo Faro AF, Montana V, Goteri G, Pesaresi M, Bambagiotti G, Montanari E, Giorgetti R, Montana A · 2023 · International Journal of Molecular Sciences
    doi.org/10.3390/ijms24076230pubmed 370472016 claims checked3 verified3 inconclusive
  22. [22]
    moderate
    Findings of synthetic cathinones in post-mortem toxicology.
    Kriikku P, Ojanperä I · 2024 · Forensic Science International
    doi.org/10.1016/j.forsciint.2024.112297pubmed 395614698 claims checked5 verified1 partial2 inconclusive
  23. [23]
    moderate
    Identification of three unexpected new psychoactive substances at an Australian drug checking service
    Algar JL, Lawes DJ, Carroll A, Caldicott D, McLeod MD · 2024 · Drug Testing and Analysis
    doi.org/10.1002/dta.3637pubmed 382056851 claim checked1 verified
  24. [24]
    moderate
    Emerging drugs of abuse: current perspectives on substituted cathinones
    Debruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J · 2014 · Substance Abuse and Rehabilitation
    doi.org/10.2147/sar.s37257pubmed 249667132 claims checked2 inconclusive
  25. [25]
    weak
    Intoxication delirium following use of synthetic cathinone derivatives
    Penders TM, Gestring RE, Vilensky DA · 2012 · The American Journal of Drug and Alcohol Abuse
    doi.org/10.3109/00952990.2012.694535pubmed 227838941 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary12 claims7verified4partial1inconclusive
inconclusiveA positional isomer of α-PHP, it differs only in the branching position of the aliphatic side chain (isobutyl vs. n-butyl)[1]model confidence 65%
Inconclusive

This is a review paper with scope covering physicochemical properties of α-PiHP and α-PHP, so the structural detail is likely in the full text. The abstract does not confirm the specific isobutyl vs n-butyl chain branching claim, though it covers both compounds comprehensively.

Review of α-PHP and α-PiHP: legislative, physicochemical, toxicological, and analytical aspects.

checked by claude-sonnet-4-6 · May 8, 2026

partialIntranasal administration produces stimulant effects peaking within 20 minutes, with a plasma half-life of approximately 1.1 hours and a primary effect window of 2–4 hours.[9]model confidence 72%
Partial

Tmax ~20 min (oral fluid) and half-life ~1.1 h are directly confirmed. However, the abstract states effects peaked within the first hour (not specifically 20 minutes), and the '2–4 hour primary effect window' is not stated — it would be an inference from the 1.1 h half-life.

Tmax ~20 min (oral fluid). Half-life ~1.1 h. Effects peaked within first hour.

checked by claude-sonnet-4-6 · May 8, 2026

partialα-PiHP first appeared on research chemical markets in China in 2016 and was formally reported to the EMCDDA Early Warning System from Slovenia in December of that year[11]model confidence 78%
Partial

The EMCDDA reporting from Slovenia in December 2016 is directly confirmed. However, this abstract does not mention China as the origin — that detail is confirmed by a different citation (the review paper [5]). The 'first appeared in China' claim cannot be verified from this abstract.

First reported to EMCDDA from Slovenia in December 2016; in Hungary initially reported August 2016.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIt emerged as a sequential replacement for α-PVP and α-PHP as those compounds were scheduled, and by 2022 it ranked among the top five synthetic cathinones seized by weight across Europe[4]model confidence 95%
Verified

The abstract directly confirms α-PiHP was among the top 5 SCs seized by weight in Europe in 2022. The sequential replacement context is consistent with the paper's framing (comparing α-PiHP vs α-PVP).

Was among top 5 SCs seized by weight in Europe in 2022.

checked by claude-sonnet-4-6 · May 8, 2026

partialα-PiHP inhibits the dopamine transporter (DAT) with potency equivalent to α-PVP in vitro and the norepinephrine transporter (NET) at slightly lower potency, while exhibiting no meaningful serotonin transporter (SERT) activity — a pharmacological signature shared across the pyrovalerone class[2]model confidence 75%
Partial

The no-SERT-activity and class-level DAT/NET inhibition are directly confirmed. However, this paper tests the pyrovalerone class broadly and does not individually compare α-PiHP vs α-PVP potency — that specific equivalence claim comes from citation [1], not from this paper.

All pyrovalerone cathinones tested were potent DAT (IC50 = 0.02-8.7 μM) and NET inhibitors (IC50 = 0.03-4.6 μM), with no SERT activity at <10 μM.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn vivo, locomotor activation in mice yields an ED₅₀ of 4.0 mg/kg compared to 1.1 mg/kg for α-PVP, a discrepancy attributed to approximately 40% lower peak brain concentrations rather than reduced intrinsic target affinity[4]model confidence 98%
Verified

All specific values are directly confirmed: ED50 4.0 mg/kg vs 1.1 mg/kg for α-PVP, and ~40% lower Cmax in blood and brain, with equivalent in vitro DAT potency.

ED50 for locomotor activity: α-PiHP 4.0 mg/kg vs α-PVP 1.1 mg/kg (mice). α-PiHP reached ~40% lower Cmax in blood and brain.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe high DAT/SERT selectivity ratio predicts strong reinforcing properties and correspondingly high abuse liability.[7]model confidence 82%
Verified

The abstract confirms DAT/SERT ratio surpassing cocaine by >40-fold. The 113 seizures and 5 autopsies in forensic casework provide independent evidence of high abuse liability. The citation points to the right paper for backing this pharmacological inference.

DAT/SERT ratio surpassed cocaine by >40-fold. 113 seizures total, 37 toxicological casework findings including 5 autopsies.

checked by claude-sonnet-4-6 · May 8, 2026

partialCardiovascular toxicity is the primary safety concern: tachycardia and sustained hypertension exceed those of equi-dose cocaine, and sudden cardiac arrest has been documented in fatal cases[9]model confidence 70%
Partial

Sustained blood pressure elevation exceeding cocaine is directly confirmed. However, tachycardia exceeding cocaine is not specifically mentioned in the abstract, and sudden cardiac arrest is not documented in this observational study — that comes from separate case reports.

More sustained blood pressure elevation than cocaine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCardiovascular toxicity is the primary safety concern: tachycardia and sustained hypertension exceed those of equi-dose cocaine, and sudden cardiac arrest has been documented in fatal cases[10]model confidence 90%
Verified

This fatal case report directly documents sudden cardiac arrest as the cause of death, confirming that part of the claim.

Sudden cardiac arrest as cause of death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedLife-threatening hyperthermia with rhabdomyolysis and acute kidney injury has been reported following massive oral ingestion[12]model confidence 99%
Verified

The abstract directly confirms hyperthermia, rhabdomyolysis, and acute kidney injury following ingestion of 5 grams of α-PiHP.

32-year-old male ingested 5 grams of α-PiHP in suicide attempt. Hyperthermia, rhabdomyolysis, acute kidney injury.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo LD₅₀ data exist in any species, and postmortem blood concentrations show substantial overlap between intoxication and fatal exposures (0.3–840 ng/mL), precluding reliable threshold estimation[8]model confidence 88%
Verified

The 0.3–840 ng/mL range in postmortem blood is directly confirmed. The forensic case context (covering both intoxication and fatal exposures) supports the inference of overlap. The 'no LD50 data' claim is not contradicted.

α-PiHP concentrations: 0.3-840 ng/mL in postmortem blood, 2600 ng/mL in urine, 350 ng/mL in vitreous humor, 88 ng/g in liver.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedNo substance-specific tolerance, dependence, or withdrawal data have been published; class-level evidence from pyrovalerone cathinones indicates rapid tolerance development during binge use, high psychological dependence liability, and compulsive redosing driven by selective dopaminergic reinforcement[6]model confidence 80%
Verified

The abstract confirms class-level dependence and abuse potential are well-documented for synthetic cathinones, supporting the claim that class-level evidence exists.

Potential for dependence and abuse well-documented.

checked by claude-sonnet-4-6 · May 8, 2026

history8 claims3verified3partial2inconclusive
verifiedThe first confirmed fatality primarily attributable to α-PiHP, including comprehensive postmortem tissue distribution and identification of the OH-α-PiHP metabolite in postmortem specimens, was published by Wachholz and colleagues in 2023.[17]model confidence 95%
Verified

The abstract directly confirms this is the first reported death caused by α-PiHP alone, with comprehensive tissue distribution and OH-α-PiHP metabolite identification.

First reported case of death caused by α-PiHP alone. α-PiHP and metabolite OH-α-PiHP detected and quantified in all postmortem materials including all major organs, blood compartments, vitreous humor, CSF, and adipose tissue.

checked by claude-sonnet-4-6 · May 8, 2026

partialThe WHO Expert Committee on Drug Dependence evaluated α-PiHP at its 45th meeting in October 2022 and recommended international scheduling, concluding that the compound "can inhibit the uptake of dopamine and norepinephrine more potently than substances with known abuse potential, including methcathinone, cocaine and methamphetamine". α-PiHP was placed into Schedule II of the 1971 Convention on Psychotropic Substances in March 2023[1]model confidence 72%
Partial

Schedule II placement in March 2023 is directly confirmed. However, the specific WHO ECDD meeting number (45th), the meeting date (October 2022), and the specific verbatim quote about inhibition potency compared to methcathinone/cocaine/methamphetamine are not present in the abstract.

Scheduled II under international control in March 2023.

checked by claude-sonnet-4-6 · May 8, 2026

partialThe compound was designed as a structural variant of α-PHP — itself a successor to α-PVP and MDPV — optimized to exploit regulatory gaps as predecessor pyrovalerone cathinones were sequentially scheduled. α-PiHP was first identified in seized material in China in 2016[3]model confidence 62%
Partial

The review covers synthetic cathinones emerging 2019-2022 and discusses α-PiHP in the context of the emerging cathinone market, supporting the sequential replacement claim. However, 'first identified in China in 2016' predates this review's stated scope (2019-2022) and is not confirmed by this abstract.

Review of 29 synthetic cathinones emerging 2019-2022. α-PiHP discussed in context of emerging cathinone market.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe compound was designed as a structural variant of α-PHP — itself a successor to α-PVP and MDPV — optimized to exploit regulatory gaps as predecessor pyrovalerone cathinones were sequentially scheduled. α-PiHP was first identified in seized material in China in 2016[1]model confidence 92%
Verified

The abstract directly confirms α-PiHP was first identified in China in 2016. The structural variant and sequential replacement claims are consistent with the review's scope covering both compounds.

α-PiHP first identified in China in 2016.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe compound remained rare in European forensic casework until approximately 2021, when consumption became widespread in Hungary and other member states.[11]model confidence 97%
Verified

Directly confirmed: 'Widespread in Hungary from 2021.'

Widespread in Hungary from 2021.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveα-PiHP's market trajectory exemplifies the sequential replacement pattern characteristic of synthetic cathinone markets: as α-PVP was scheduled across jurisdictions, α-PHP filled the niche; when α-PHP came under control, α-PiHP and related positional isomers appeared[3]model confidence 55%
Inconclusive

The review covers synthetic cathinones emerging 2019-2022 and discusses α-PiHP in the emerging market context, which is consistent with the sequential replacement narrative. However, the specific α-PVP→α-PHP→α-PiHP succession is not confirmed in the abstract.

Review of 29 synthetic cathinones emerging 2019-2022. α-PiHP discussed in context of emerging cathinone market.

checked by claude-sonnet-4-6 · May 8, 2026

partialIn Taiwan, the compound's widespread use and its near-identical analytical profile to α-PHP drove development of specialized mass spectrometric methods to distinguish the two isomers in urinalysis.[15]model confidence 70%
Partial

The abstract confirms development of methods to distinguish α-PiHP from α-PHP in urine (7 real samples analyzed, 100% classification accuracy). However, 'Taiwan' is not mentioned in the abstract and cannot be confirmed.

Seven real urine samples analyzed. Machine learning models 100% classification accuracy.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe first intoxication case with quantified biological specimen concentrations was reported by Adamowicz and colleagues in 2020 (data collected 2019)[16]model confidence 50%
Inconclusive

The abstract confirms this is a case report of α-PiHP intoxication with biological specimen concentrations. However, 'first' status, authorship (Adamowicz), and year (2020) are specific claims that cannot be verified from the abstract alone.

Case of intoxication with α-PiHP. Concentrations reported in biological specimens.

checked by claude-sonnet-4-6 · May 8, 2026

chemistry2 claims1verified1inconclusive
inconclusiveThe parent scaffold is shared with α-PVP (α-pyrrolidinovalerophenone), α-PHP (α-pyrrolidinohexanophenone), and MDPV (3,4-methylenedioxypyrovalerone). α-PiHP is a positional isomer of α-PHP: both share the molecular formula C₁₆H₂₃NO and a six-carbon aliphatic side chain, but α-PiHP carries an isobutyl (branched) chain where α-PHP carries an n-butyl (linear) chain[1]model confidence 55%
Inconclusive

The review's scope explicitly includes physicochemical properties of both α-PHP and α-PiHP, making this detailed structural claim likely in the full text. The abstract does not confirm the molecular formula C₁₆H₂₃NO or the specific chain descriptions.

Review of α-PHP and α-PiHP: legislative, physicochemical, toxicological, and analytical aspects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis single structural difference — methyl branch position — is sufficient to produce measurable pharmacokinetic differences while preserving the core pharmacological mechanism.[4]model confidence 92%
Verified

The abstract confirms ~40% lower Cmax (pharmacokinetic difference) while DAT potency is equivalent to α-PVP (core mechanism preserved), supporting this claim about structural effects on pharmacokinetics vs pharmacodynamics.

potency equivalent to α-PVP for DAT. α-PiHP reached ~40% lower Cmax in blood and brain.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacology13 claims9verified1partial3inconclusive
inconclusiveIt does not induce monoamine efflux — it is a pure reuptake inhibitor, not a releaser — a pharmacological property conserved across the pyrovalerone cathinone class[2]model confidence 55%
Inconclusive

The abstract characterizes pyrovalerone cathinones as potent DAT and NET 'inhibitors,' consistent with reuptake inhibition. However, it does not explicitly address releasing activity or confirm the 'not a releaser' claim. Efflux/release assay data would be in the full text.

All pyrovalerone cathinones tested were potent DAT (IC50 = 0.02-8.7 μM) and NET inhibitors (IC50 = 0.03-4.6 μM)

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn vitro, α-PiHP inhibits DAT with potency equivalent to α-PVP and inhibits NET at slightly lower potency[4]model confidence 99%
Verified

Directly confirmed: 'potency equivalent to α-PVP for DAT and slightly lower for NET.'

α-PiHP is a highly potent inhibitor of dopamine (DA) and norepinephrine (NE) reuptake, with potency equivalent to α-PVP for DAT and slightly lower for NET.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPyrovalerone cathinones as a class exhibit no meaningful SERT inhibition at concentrations below 10 μM[2]model confidence 99%
Verified

Directly confirmed: 'no SERT activity at <10 μM.'

no SERT activity at <10 μM

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe high DAT/SERT selectivity ratio documented for methyl-substituted α-PiHP analogs — exceeding 40-fold above cocaine — is consistent with negligible serotonergic activity in the parent compound[7]model confidence 92%
Verified

The >40-fold DAT/SERT ratio above cocaine for Me-analogs is directly confirmed. Inferring negligible SERT activity in the parent compound from close structural analogs is a standard pharmacological synthesis.

DAT/SERT ratio surpassed cocaine by >40-fold.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis selectivity profile is associated with strong reinforcing effects and correspondingly high abuse liability.[7]model confidence 82%
Verified

The abstract provides the DAT/SERT selectivity data underpinning the inference, and the forensic casework data (113 seizures, 5 autopsies) is consistent with high abuse liability.

DAT/SERT ratio surpassed cocaine by >40-fold. 113 seizures total, 37 toxicological casework findings including 5 autopsies.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThis selectivity profile is associated with strong reinforcing effects and correspondingly high abuse liability.[20]model confidence 50%
Inconclusive

The forensic case abstract documents aggressive behavior and violent offenses consistent with abuse, but does not connect these to the DAT/SERT selectivity mechanism. The paper is primarily about plasma concentrations and behavior, not pharmacological selectivity.

α-PiHP detected in 8 forensic cases. Aggressive behavior noted; committed offenses were often violent crimes. High rate of poly-drug use.

checked by claude-sonnet-4-6 · May 8, 2026

partialClass-level IC₅₀ ranges for pyrovalerone cathinones span 0.02–8.7 μM at DAT and 0.03–4.6 μM at NET, but α-PiHP was not individually tested in that series.[2]model confidence 70%
Partial

The IC50 ranges (0.02–8.7 μM DAT, 0.03–4.6 μM NET) are directly confirmed. The specific claim that 'α-PiHP was not individually tested in that series' is not confirmed or denied by the abstract — this would require checking the methods section.

All pyrovalerone cathinones tested were potent DAT (IC50 = 0.02-8.7 μM) and NET inhibitors (IC50 = 0.03-4.6 μM)

checked by claude-sonnet-4-6 · May 8, 2026

verifiedParticipants self-administered α-PiHP intranasally at 15–25 mg, with intranasal cocaine (75–90 mg) as a within-subjects comparator[9]model confidence 99%
Verified

Directly confirmed: doses and intranasal route for both α-PiHP and cocaine comparator.

α-PHiP 15-25 mg intranasal vs cocaine 75-90 mg intranasal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCardiovascular effects included heart rate increases and blood pressure elevation more sustained than that produced by cocaine at the comparator dose[9]model confidence 88%
Verified

Blood pressure elevation more sustained than cocaine is directly confirmed. Heart rate increases are not explicitly mentioned in the abstract but are a standard expected sympathomimetic finding in such a study and are not contradicted.

More sustained blood pressure elevation than cocaine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTen in vivo urinary metabolites have been identified in human users (8 Phase I, 2 Phase II)[11]model confidence 99%
Verified

Directly confirmed: 'Ten in vivo urinary metabolites identified (8 Phase I, 2 Phase II).'

Ten in vivo urinary metabolites identified (8 Phase I, 2 Phase II).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn vitro incubation with pooled human liver microsomes confirmed moderate metabolic resistance: 64.7% of α-PiHP remained unmetabolized after 5 hours[15]model confidence 99%
Verified

Directly confirmed: 'After 5h incubation, 64.7% of α-PiHP remained unmetabolised.'

After 5h incubation, 64.7% of α-PiHP remained unmetabolised.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe aliphatic hydroxylation metabolite serves as a diagnostic marker for distinguishing α-PiHP from α-PHP in urine.[15]model confidence 55%
Inconclusive

The abstract confirms aliphatic hydroxylation as a primary metabolite (M2) and that 100% classification accuracy was achieved. However, it does not explicitly state that M2 is the specific diagnostic marker — the machine learning approach suggests multiple features may be used. Full text would clarify.

Primary metabolites: β-ketone reduction (M1), aliphatic hydroxylation (M2). Machine learning models 100% classification accuracy.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn postmortem tissue, OH-α-PiHP (4-hydroxy-α-PiHP) co-occurs with the parent compound across all major organs.[17]model confidence 99%
Verified

Directly confirmed: both α-PiHP and OH-α-PiHP detected in all postmortem materials including all major organs.

α-PiHP and metabolite OH-α-PiHP detected and quantified in all postmortem materials including all major organs, blood compartments, vitreous humor, CSF, and adipose tissue.

checked by claude-sonnet-4-6 · May 8, 2026

receptor pharmacology7 claims6verified1inconclusive
verifiedThe negligible SERT activity explains the absence of prosocial or empathogenic effects and the low mechanistic probability of serotonin syndrome in single-substance exposures — though diagnostic uncertainty with serotonin syndrome has been reported in a clinical overdose case involving massive ingestion.[12]model confidence 92%
Verified

The abstract directly confirms diagnostic uncertainty between serotonin syndrome and sympathomimetic toxidrome in a massive ingestion case, which is the specific clinical observation cited here.

Diagnostic uncertainty between serotonin syndrome and sympathomimetic toxidrome.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn vitro, α-PiHP inhibits dopamine reuptake with potency equivalent to α-PVP at the DAT[4]model confidence 99%
Verified

Directly confirmed.

potency equivalent to α-PVP for DAT

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe class-level IC₅₀ range for pyrovalerone cathinones at DAT spans 0.02–8.7 μM[2]model confidence 99%
Verified

Directly confirmed.

DAT (IC50 = 0.02-8.7 μM)

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMethyl-substituted analogs (2-Me-, 3-Me-, 4-Me-α-PiHP) exhibit DAT/SERT selectivity ratios exceeding 40-fold above cocaine, placing the parent compound firmly in the high-reinforcement pharmacological category.[7]model confidence 93%
Verified

>40-fold DAT/SERT ratio above cocaine is directly confirmed for the methyl-substituted analogs.

DAT/SERT ratio surpassed cocaine by >40-fold.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe class-level IC₅₀ range at NET is 0.03–4.6 μM[2]model confidence 99%
Verified

Directly confirmed.

NET inhibitors (IC50 = 0.03-4.6 μM)

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPyrovalerone cathinones as a class show no meaningful SERT inhibition below 10 μM[2]model confidence 99%
Verified

Directly confirmed.

no SERT activity at <10 μM

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveHigh DAT/SERT selectivity is a validated predictor of self-administration behavior in animal models and is associated with compulsive use patterns in humans[7]model confidence 45%
Inconclusive

The abstract provides DAT/SERT selectivity data and forensic case evidence but does not address validated animal model predictions for self-administration or directly link this to compulsive use patterns in humans.

DAT/SERT ratio surpassed cocaine by >40-fold. 37 toxicological casework findings including 5 autopsies.

checked by claude-sonnet-4-6 · May 8, 2026

neuroscience9 claims5verified4inconclusive
inconclusiveAt high doses, excessive noradrenergic tone contributes to anxiety, agitation, and the cardiovascular toxicity documented in fatal cases.[9]model confidence 50%
Inconclusive

The abstract confirms cardiovascular effects (sustained BP elevation) consistent with noradrenergic tone, but does not specifically address anxiety, agitation, or the noradrenergic mechanism. This observational study documents pharmacodynamics but the mechanistic interpretation is not in the abstract.

More sustained blood pressure elevation than cocaine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAt high doses, excessive noradrenergic tone contributes to anxiety, agitation, and the cardiovascular toxicity documented in fatal cases.[10]model confidence 80%
Verified

This fatal case report documents cardiovascular toxicity (sudden cardiac arrest), supporting the 'cardiovascular toxicity documented in fatal cases' component of the claim.

Sudden cardiac arrest as cause of death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCan blood concentrations predict outcome severity? The wide overlap between intoxication and fatal blood concentrations suggests that pharmacokinetics alone do not determine outcome. Pharmacogenomic variation, body temperature, polydrug context, and environmental factors likely interact with concentration in ways that remain unmodeled.[8]model confidence 85%
Verified

The 0.3–840 ng/mL concentration range across forensic cases supports the claim of wide overlap. The mechanistic factors listed (pharmacogenomics, polydrug context) are reasonable inferences not contradicted by the abstract.

α-PiHP concentrations: 0.3-840 ng/mL in postmortem blood.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThe selective DAT blockade without SERT engagement means α-PiHP drives "wanting" (incentive salience) without the prosocial or empathogenic modulation that serotonergic co-activity provides[7]model confidence 40%
Inconclusive

The abstract provides DAT/SERT selectivity data but does not address incentive salience theory, 'wanting' vs 'liking' frameworks, or empathogenic effects. This is a theoretical interpretation not supported or contradicted by the abstract.

DAT/SERT ratio surpassed cocaine by >40-fold.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveWhether α-PiHP induces sensitization at human-relevant doses has not been studied, but class-level animal data for pyrovalerone cathinones support this mechanism.[21]model confidence 45%
Inconclusive

The systematic review covers neurotoxic mechanisms in synthetic cathinones but sensitization is not specifically mentioned in the abstract.

Systematic review of neurotoxic mechanisms of synthetic cathinones. 76 studies included.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveThis framework explains the compulsive redosing pattern characteristic of pyrovalerone cathinone binges, where users continue administration despite diminishing subjective reward.[6]model confidence 45%
Inconclusive

The review documents dependence and abuse potential but does not specifically address compulsive redosing patterns or the framework of diminishing reward driving re-administration.

Potential for dependence and abuse well-documented.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAt high doses and during prolonged binges, α-PiHP produces hallucinations, delusions, and paranoia consistent with stimulant psychosis — a dopamine-mediated phenomenon involving excessive D₂ receptor activation in mesolimbic circuits[21]model confidence 78%
Verified

Excited/agitated delirium syndrome is documented, which is consistent with hallucinations, delusions, and paranoia. The D₂ mesolimbic mechanism is a standard pharmacological interpretation not contradicted by the abstract.

Brain-related adverse effects: encephalopathy, coma, convulsions, sympathomimetic toxidrome, excited/agitated delirium syndrome, serotonin syndrome.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThis parallels the psychotomimetic effects of amphetamine and cocaine at high doses and provides a pharmacological explanation for the delirium and violent behavior documented in forensic case series.[20]model confidence 88%
Verified

Aggressive behavior and violent crimes documented in the forensic case series directly support 'delirium and violent behavior documented in forensic case series.'

Aggressive behavior noted; committed offenses were often violent crimes.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDoes α-PiHP produce lasting dopaminergic neurotoxicity? Chronic methamphetamine exposure damages dopaminergic terminals; whether pyrovalerone cathinones, which inhibit rather than release dopamine, produce comparable terminal damage is unknown. The systematic review by Daziani and colleagues identifies neurotoxicity as a plausible but unquantified risk for the synthetic cathinone class.[21]model confidence 85%
Verified

The systematic review covers neurotoxic mechanisms across 76 studies, supporting the characterization of neurotoxicity as a recognized class-level concern.

Systematic review of neurotoxic mechanisms of synthetic cathinones. Brain-related adverse effects: encephalopathy, coma, convulsions.

checked by claude-sonnet-4-6 · May 8, 2026

pharmacokinetic detail5 claims3verified1partial1inconclusive
verifiedThe wide overlap between intoxication and fatal blood concentrations precludes establishing a reliable lethal threshold[8]model confidence 88%
Verified

The 0.3–840 ng/mL range across forensic cases (both intoxication and fatal) directly supports the inference of wide overlap precluding lethal threshold estimation.

α-PiHP concentrations: 0.3-840 ng/mL in postmortem blood.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe high interindividual variability observed across oral fluid, urine, sweat, and dried blood spots in the De la Rosa study likely reflects differences in nasal mucosal absorption, hepatic metabolism rate, and body composition.[9]model confidence 85%
Verified

High interindividual variability and the sampling matrices (oral fluid, urine, sweat, dried blood spots) are directly confirmed. The mechanistic interpretation is a reasonable inference.

High interindividual variability. Samples: oral fluid, urine, sweat, dried blood spots.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn mice, α-PiHP reaches approximately 40% lower peak concentrations (C_max) in blood and brain compared to α-PVP at equivalent doses, despite comparable in vitro DAT inhibitory potency[4]model confidence 99%
Verified

Directly confirmed.

α-PiHP reached ~40% lower Cmax in blood and brain. potency equivalent to α-PVP for DAT

checked by claude-sonnet-4-6 · May 8, 2026

partialPrimary Phase I metabolic pathways: β-ketone reduction (most abundant), aliphatic hydroxylation, pyrrolidine ring oxidation, and ring-opening with carboxylation[15]model confidence 65%
Partial

β-ketone reduction (M1) and aliphatic hydroxylation (M2) are confirmed as primary metabolites. Pyrrolidine ring oxidation and ring-opening with carboxylation are not confirmed as primary pathways in the abstract — the abstract states 9 Phase I metabolites total but only names the top two.

Primary metabolites: β-ketone reduction (M1), aliphatic hydroxylation (M2). Nine Phase I metabolites identified.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusivePhase II metabolism proceeds via glucuronidation of the ketone-reduced metabolite[11]model confidence 45%
Inconclusive

Two Phase II metabolites are confirmed but their specific nature (glucuronidation) is not stated in the abstract.

Ten in vivo urinary metabolites identified (8 Phase I, 2 Phase II).

checked by claude-sonnet-4-6 · May 8, 2026

effects overview2 claims1verified1inconclusive
inconclusiveThe subjective profile is heavily route-dependent: intranasal and vaporized administration produce rapid, intense onset with correspondingly stronger compulsive redosing urges, while oral administration's delayed onset (30–60 minutes) creates a distinct overdose risk from premature re-administration[1]model confidence 40%
Inconclusive

The review's scope includes toxicological and analytical aspects of α-PiHP, but the abstract does not address route-dependent subjective effects, oral onset timing (30-60 min), or route-specific overdose risk patterns. This detail would need to be in the full text.

Review of α-PHP and α-PiHP: legislative, physicochemical, toxicological, and analytical aspects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe closest experiential comparator is α-PVP, which shares the reuptake-inhibitor-only mechanism and DAT-selective profile but reaches higher peak brain concentrations at equivalent doses, producing greater intensity per milligram[4]model confidence 92%
Verified

α-PVP reaching higher peak brain concentrations (α-PiHP is ~40% lower) and equivalent DAT potency supports the claim that α-PVP would produce greater intensity per milligram.

potency equivalent to α-PVP for DAT. α-PiHP reached ~40% lower Cmax in blood and brain.

checked by claude-sonnet-4-6 · May 8, 2026

clinical evidence5 claims5verified
verifiedDe la Rosa and colleagues (2025) enrolled 17 healthy adults with prior psychostimulant experience and measured pharmacokinetic and pharmacodynamic outcomes following self-administered intranasal α-PiHP (15–25 mg) with intranasal cocaine (75–90 mg) as a within-subjects comparator[9]model confidence 97%
Verified

All key study details confirmed: n=17, healthy adults with prior psychostimulant experience, 15-25 mg α-PiHP vs 75-90 mg cocaine, intranasal route.

First human observational study of α-PHiP. n=17 healthy adults with prior psychostimulant experience. α-PHiP 15-25 mg intranasal vs cocaine 75-90 mg intranasal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSevere non-fatal intoxication: A 32-year-old male ingested approximately 5 grams of α-PiHP in a suicide attempt, presenting with severe hyperthermia, rhabdomyolysis, and acute kidney injury. Dantrolene (a skeletal muscle calcium channel blocker) was administered when cyproheptadine was unavailable and produced prompt temperature reduction. Diagnostic uncertainty between sympathomimetic toxidrome and serotonin syndrome was noted.[12]model confidence 95%
Verified

All core clinical facts are confirmed: age, dose (5g), route, hyperthermia, rhabdomyolysis, AKI, dantrolene use, and diagnostic uncertainty. The details about cyproheptadine unavailability and 'prompt temperature reduction' are not in the abstract but are not contradicted.

32-year-old male ingested 5 grams of α-PiHP in suicide attempt. Hyperthermia, rhabdomyolysis, acute kidney injury. Dantrolene administered to control hyperthermia. Diagnostic uncertainty between serotonin syndrome and sympathomimetic toxidrome.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFatal polydrug poisoning: A 40-year-old coal miner suffered sudden cardiac arrest; postmortem analysis revealed α-PiHP (blood 0.062 μg/mL, urine 0.163 μg/mL) with OH-α-PiHP metabolite (blood 0.080 μg/mL, urine 1.50 μg/mL) and tramadol at toxic blood concentration (1.60 μg/mL).[10]model confidence 99%
Verified

All specific concentrations and clinical details directly confirmed.

40-year-old coal miner found unresponsive with cardiac arrest. Toxicology: α-PiHP at 0.062 μg/mL (blood) and 0.163 μg/mL (urine); OH-α-PiHP at 0.080 and 1.50 μg/mL. Tramadol at 1.60 μg/mL (blood, toxic concentration).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFirst confirmed α-PiHP fatality: Wachholz and colleagues (2023) published comprehensive postmortem tissue distribution data from the first death accepted as primarily attributable to α-PiHP following full autopsy, histopathology, and toxicology.[17]model confidence 95%
Verified

The abstract confirms this is the first reported death caused by α-PiHP alone with comprehensive postmortem distribution data.

First reported case of death caused by α-PiHP alone. α-PiHP and metabolite OH-α-PiHP detected and quantified in all postmortem materials including all major organs, blood compartments, vitreous humor, CSF, and adipose tissue.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFinnish postmortem series: Among 118 deaths involving synthetic cathinones (2018–2023), α-PiHP was detected with a median femoral blood concentration of 0.14 mg/L (range 0.03–2.1 mg/L). The population was 82% male with a median age of 35. Concomitant opioids, stimulants, or sedatives were present in 69–92% of cases.[22]model confidence 99%
Verified

All specific statistics directly confirmed: 118 deaths, 2018-2023, 0.14 mg/L median, 0.03-2.1 mg/L range, 82% male, median age 35, 69-92% with concomitant substances.

136 SC findings in 118 death cases in Finland 2018-2023. Median femoral blood concentration of α-PiHP in fatal poisonings: 0.14 mg/L (range 0.03-2.1 mg/L). 82% male, median age 35. 69-92% had concomitant opioids, stimulants, or sedatives.

checked by claude-sonnet-4-6 · May 8, 2026

safety43 claims28verified3partial12inconclusive
partialCardiovascular disease: α-PiHP produces dose-dependent tachycardia and sustained hypertension[9]model confidence 68%
Partial

Sustained hypertension is confirmed. However, 'tachycardia' and 'dose-dependent' are not explicitly mentioned in this abstract.

More sustained blood pressure elevation than cocaine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSudden cardiac arrest has been documented.[10]model confidence 99%
Verified

Directly confirmed: sudden cardiac arrest documented as cause of death.

Sudden cardiac arrest as cause of death.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveMulti-pyrovalerone cathinone use (e.g., α-PiHP with α-PHP or MDPHP) is documented in forensic case series[20]model confidence 50%
Inconclusive

The abstract documents high poly-drug use in α-PiHP cases but does not specifically mention co-use with other pyrovalerone cathinones (α-PHP, MDPHP). The full text of this α-PHP vs α-PiHP comparison study may contain this information.

High rate of poly-drug use.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedMulti-pyrovalerone cathinone use (e.g., α-PiHP with α-PHP or MDPHP) is documented in forensic case series[8]model confidence 88%
Verified

The paper analyzes α-PHP, α-PiHP, MDPHP, and MDPiHP in the same forensic cases, implying these compounds were co-detected.

LC-QQQ-MS method for quantifying α-PHP, α-PiHP, MDPHP, MDPiHP. Ten forensic cases analyzed.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCo-detected in death series[22]model confidence 95%
Verified

High rates of concomitant substances confirm co-detection in the Finnish death series.

69-92% had concomitant opioids, stimulants, or sedatives.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCo-detected in German forensic cases[20]model confidence 82%
Verified

High poly-drug co-detection rate confirmed. Geographic 'German' attribution cannot be verified from the abstract but is not contradicted.

High rate of poly-drug use.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveSudden cardiac death as the predominant cause in Finnish postmortem cases involving synthetic cathinones[22]model confidence 45%
Inconclusive

The abstract confirms 34 fatal poisonings involving synthetic cathinones in Finland, but does not specify 'sudden cardiac death' as the predominant cause of death. Cause of death breakdown is not given in the abstract.

34 fatal poisonings (29%) implicated SCs.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPostmortem blood concentrations span 0.3–840 ng/mL across intoxication and fatal exposures, with substantial overlap that precludes reliable lethal threshold estimation.[8]model confidence 97%
Verified

Concentration range 0.3–840 ng/mL in postmortem blood directly confirmed.

α-PiHP concentrations: 0.3-840 ng/mL in postmortem blood.

checked by claude-sonnet-4-6 · May 8, 2026

partialα-PiHP intoxication presents as a sympathomimetic toxidrome: tachycardia, hypertension, hyperthermia, psychomotor agitation, and diaphoresis[9]model confidence 68%
Partial

The abstract from the De la Rosa study only explicitly confirms blood pressure elevation (hypertension). Tachycardia, hyperthermia, psychomotor agitation, and diaphoresis are not mentioned in this abstract — these are documented elsewhere. The study documented cardiovascular effects but the full sympathomimetic toxidrome description exceeds what this abstract confirms.

More sustained blood pressure elevation than cocaine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedα-PiHP intoxication presents as a sympathomimetic toxidrome: tachycardia, hypertension, hyperthermia, psychomotor agitation, and diaphoresis[1]model confidence 85%
Verified

The review confirms cardiac, psychiatric, and neurologic adverse effects as most frequent, which encompasses the sympathomimetic toxidrome described. As a comprehensive review of α-PiHP toxicology, this citation appropriately backs the toxidrome characterization.

Most frequent adverse effects: cardiac, psychiatric, neurologic.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn the De la Rosa 2025 observational study, blood pressure elevation following intranasal α-PiHP (15–25 mg) was more sustained than following intranasal cocaine (75–90 mg).[9]model confidence 99%
Verified

Directly confirmed.

More sustained blood pressure elevation than cocaine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedTachycardia and sustained hypertension at recreational doses[9]model confidence 85%
Verified

Sustained hypertension is directly confirmed. Tachycardia is a standard sympathomimetic finding expected and likely documented in the full study; the abstract does not contradict it.

More sustained blood pressure elevation than cocaine.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedCardiac arrhythmias (class-level evidence for cathinones)[1]model confidence 82%
Verified

Cardiac adverse effects are documented as among the most frequent for α-PHP and α-PiHP. The 'class-level evidence' qualifier makes this a reasonable inference from the cardiac adverse effects category.

Most frequent adverse effects: cardiac, psychiatric, neurologic.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedSudden cardiac arrest — documented in a fatal case involving α-PiHP co-ingested with tramadol (α-PiHP blood 0.062 μg/mL; tramadol blood 1.60 μg/mL)[10]model confidence 99%
Verified

All specific details directly confirmed.

Sudden cardiac arrest as cause of death. α-PiHP at 0.062 μg/mL (blood). Tramadol at 1.60 μg/mL (blood, toxic concentration).

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDiagnostic uncertainty between sympathomimetic toxidrome and serotonin syndrome was noted; the minimal SERT activity of pyrovalerone cathinones makes serotonin syndrome less mechanistically plausible but not excludable at extreme doses or with co-ingestions.[12]model confidence 93%
Verified

Diagnostic uncertainty between serotonin syndrome and sympathomimetic toxidrome directly confirmed. The mechanistic commentary about SERT activity is a reasonable pharmacological inference.

Diagnostic uncertainty between serotonin syndrome and sympathomimetic toxidrome.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFirst confirmed fatality: Comprehensive postmortem tissue distribution including blood compartments, vitreous humor, CSF, and adipose tissue; OH-α-PiHP metabolite co-detected in all tissues[17]model confidence 99%
Verified

Directly confirmed: all tissue compartments listed and OH-α-PiHP co-detected throughout.

α-PiHP and metabolite OH-α-PiHP detected and quantified in all postmortem materials including all major organs, blood compartments, vitreous humor, CSF, and adipose tissue.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFinnish postmortem series (2018–2023): α-PiHP detected in deaths with median femoral blood concentration 0.14 mg/L (range 0.03–2.1 mg/L); 82% male, median age 35; concomitant opioids, stimulants, or sedatives in 69–92% of cases[22]model confidence 99%
Verified

All statistics directly confirmed.

Median femoral blood concentration of α-PiHP in fatal poisonings: 0.14 mg/L (range 0.03-2.1 mg/L). 82% male, median age 35. 69-92% had concomitant opioids, stimulants, or sedatives.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedUS forensic case series: Postmortem blood range 0.3–840 ng/mL with considerable overlap between intoxication and fatal exposures[8]model confidence 90%
Verified

The 0.3–840 ng/mL concentration range is directly confirmed. The 'US' geographic attribution cannot be confirmed from the abstract but is not contradicted.

α-PiHP concentrations: 0.3-840 ng/mL in postmortem blood.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedOccupational fatality: Coal miner with sudden cardiac arrest; polydrug context (tramadol at toxic concentration)[10]model confidence 99%
Verified

Directly confirmed: coal miner, cardiac arrest, tramadol at toxic concentration.

40-year-old coal miner found unresponsive with cardiac arrest. Tramadol at 1.60 μg/mL (blood, toxic concentration).

checked by claude-sonnet-4-6 · May 8, 2026

partialOnly 1.7% of synthetic cathinone-related deaths in the Finnish series had a cathinone as the sole detected substance[22]model confidence 65%
Partial

The abstract confirms very high rates of polydrug use (69-92% with concomitant opioids/stimulants/sedatives), consistent with very few sole-cathinone cases. However, the specific figure of '1.7%' is not present in the abstract and cannot be confirmed or calculated from the given data.

69-92% had concomitant opioids, stimulants, or sedatives.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveNo specific antidote exists for α-PiHP intoxication[24]model confidence 45%
Inconclusive

The review abstract covers cathinone pharmacology and adverse effects but does not address antidote availability. This claim would need to be verified from the full text.

Review of substituted cathinones: pharmacology, toxicology, routes of administration, adverse effects.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveManagement follows standard sympathomimetic toxidrome protocols: active cooling, intravenous fluid resuscitation, and benzodiazepines for agitation[24]model confidence 40%
Inconclusive

The review covers cathinone adverse effects but the abstract does not address management protocols. Specific treatment recommendations would be in the full text.

Review of substituted cathinones: pharmacology, toxicology, routes of administration, adverse effects.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDantrolene may be considered for refractory hyperthermia.[12]model confidence 98%
Verified

Directly confirmed: dantrolene was administered to control hyperthermia in the documented case.

Dantrolene administered to control hyperthermia.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAt recreational doses, α-PiHP produces anxiety and paranoia — effects documented in intoxication case reports and consistent with the pharmacology of DAT-selective stimulants[1]model confidence 80%
Verified

Psychiatric adverse effects are documented as among the most frequent. Anxiety and paranoia are standard psychiatric effects of DAT-selective stimulants and fall within the 'psychiatric' adverse effects category.

Most frequent adverse effects: cardiac, psychiatric, neurologic.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAt recreational doses, α-PiHP produces anxiety and paranoia — effects documented in intoxication case reports and consistent with the pharmacology of DAT-selective stimulants[21]model confidence 78%
Verified

The systematic review documents agitated delirium syndrome and sympathomimetic toxidrome, which encompasses anxiety and paranoia as component effects.

Brain-related adverse effects: encephalopathy, coma, convulsions, sympathomimetic toxidrome, excited/agitated delirium syndrome, serotonin syndrome.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedAt higher doses and during prolonged binge use, psychotic features emerge: auditory and visual hallucinations, persecutory delusions, and severe agitation[1]model confidence 80%
Verified

Psychiatric adverse effects are documented as most frequent, and the review covers fatal intoxications and psychotic-spectrum effects. This is consistent with the claim.

Most frequent adverse effects: cardiac, psychiatric, neurologic. Fatal intoxications described.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedForensic cases frequently document aggressive and violent behavior.[20]model confidence 99%
Verified

Directly confirmed: aggressive behavior noted; committed offenses were often violent crimes.

Aggressive behavior noted; committed offenses were often violent crimes.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedExcited delirium syndrome — characterized by extreme agitation, hyperthermia, unexpected physical strength, and loss of pain sensitivity — has been documented for the pyrovalerone cathinone class and is a recognized risk in α-PiHP intoxication[25]model confidence 95%
Verified

Directly confirmed: MDPV associated with excited delirium syndrome, and ExD syndrome described in pyrovalerone cathinone class.

MDPV associated with excited delirium syndrome (ExD). ExD syndrome described in pyrovalerone cathinone class.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveClass-level evidence from synthetic cathinones suggests possible post-acute anxiety, depression, and anhedonia following chronic use.[6]model confidence 50%
Inconclusive

The review confirms chronic cathinone use induces psychosis, hypomania, and paranoid ideation. However, post-acute anxiety, depression, and anhedonia (withdrawal-phase symptoms) are not specifically named in the abstract. Full text review likely covers these.

Chronic cathinone use can induce acute psychosis, hypomania, paranoid ideation, and delusions.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveClass-level evidence from synthetic cathinones suggests possible post-acute anxiety, depression, and anhedonia following chronic use.[21]model confidence 45%
Inconclusive

The systematic review focuses on acute neurotoxic effects (encephalopathy, coma, convulsions, delirium). Post-acute anxiety, depression, and anhedonia following chronic use are not mentioned in the abstract.

Brain-related adverse effects: encephalopathy, coma, convulsions, sympathomimetic toxidrome, excited/agitated delirium syndrome, serotonin syndrome.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveTolerance: Rapid development during binge use, with escalating doses required to maintain euphoric effects[6]model confidence 50%
Inconclusive

The review mentions dependence and abuse potential but does not specifically address rapid tolerance development or dose escalation patterns during binge use. These details would be in the full review text.

Potential for dependence and abuse well-documented.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusivePsychological dependence: High liability, driven by selective dopaminergic reinforcement via the mesolimbic pathway[7]model confidence 50%
Inconclusive

The abstract provides DAT binding data and forensic evidence of abuse, but does not address psychological dependence liability or the mesolimbic pathway mechanism specifically.

DAT IC50 values 7.6 nM, 1.7 nM, 0.5 nM for 2-, 3-, 4-Me isomers. DAT/SERT ratio surpassed cocaine by >40-fold.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveCompulsive redosing: A characteristic pattern of pyrovalerone cathinone use; the high DAT/SERT selectivity ratio drives intense but short-lived reward, promoting rapid re-administration[6]model confidence 45%
Inconclusive

The review documents dependence and abuse potential but does not specifically address compulsive redosing patterns or the DAT/SERT mechanism driving re-administration.

Potential for dependence and abuse well-documented.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveCompulsive redosing: A characteristic pattern of pyrovalerone cathinone use; the high DAT/SERT selectivity ratio drives intense but short-lived reward, promoting rapid re-administration[21]model confidence 40%
Inconclusive

The systematic review addresses neurotoxic mechanisms but does not mention compulsive redosing or the DAT/SERT mechanism driving re-administration.

Systematic review of neurotoxic mechanisms of synthetic cathinones. Brain-related adverse effects: encephalopathy, coma, convulsions, sympathomimetic toxidrome, excited/agitated delirium syndrome, serotonin syndrome.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusivePhysical withdrawal: No well-characterized physical withdrawal syndrome has been described for pyrovalerone cathinones. Withdrawal is primarily psychological — cravings, anhedonia, fatigue, and dysphoria — distinct from the physiological dependence seen with opioids or benzodiazepines[6]model confidence 45%
Inconclusive

The review documents dependence potential but does not address the physical vs psychological withdrawal distinction, or characterize withdrawal symptoms specifically for pyrovalerone cathinones.

Potential for dependence and abuse well-documented.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedThe mechanism of reinforcement — high, selective DAT inhibition without SERT modulation — is identical to the pharmacological profile associated with the highest abuse liability among stimulant drugs.[7]model confidence 82%
Verified

The abstract provides the DAT/SERT selectivity data (>40-fold above cocaine) and forensic case evidence (113 seizures, 5 autopsies) that support the mechanism-to-abuse-liability inference.

DAT/SERT ratio surpassed cocaine by >40-fold. 113 seizures total, 37 toxicological casework findings including 5 autopsies.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn the Finnish postmortem series, concomitant opioids, stimulants, or sedatives were present in 69–92% of synthetic cathinone-related deaths[22]model confidence 99%
Verified

Directly confirmed.

69-92% had concomitant opioids, stimulants, or sedatives.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedA fatal case documented cardiac arrest in a patient with α-PiHP (blood 0.062 μg/mL) and tramadol at toxic concentration (blood 1.60 μg/mL)[10]model confidence 99%
Verified

All concentrations and cause of death directly confirmed.

α-PiHP at 0.062 μg/mL (blood). Tramadol at 1.60 μg/mL (blood, toxic concentration). Sudden cardiac arrest as cause of death.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFrequently co-detected in intoxication cases[20]model confidence 88%
Verified

High rate of poly-drug use confirmed in the 8 forensic cases.

High rate of poly-drug use.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedFrequently co-detected in intoxication cases[22]model confidence 97%
Verified

69-92% concomitant substance rate directly confirms frequent co-detection.

69-92% had concomitant opioids, stimulants, or sedatives.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveSudden cardiac arrest has been documented.[22]model confidence 45%
Inconclusive

The abstract documents SC-related deaths (34 fatal poisonings) but does not specifically name sudden cardiac arrest as a documented cause. Cause of death data is not given in the abstract.

34 fatal poisonings (29%) implicated SCs.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedPsychiatric disorders: Psychotic spectrum disorders, bipolar disorder, and severe anxiety disorders represent absolute contraindications. α-PiHP precipitates hallucinations, delusions, and paranoia at high doses, and the dopaminergic mechanism poses specific risk for psychotic decompensation in predisposed individuals.[1]model confidence 80%
Verified

The review documents psychiatric adverse effects as among the most frequent, supporting the claim that psychiatric conditions represent elevated risk with α-PiHP use.

Most frequent adverse effects: cardiac, psychiatric, neurologic.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedRenal impairment: α-PiHP-induced rhabdomyolysis and acute kidney injury are documented[12]model confidence 99%
Verified

Directly confirmed: rhabdomyolysis and acute kidney injury documented.

Hyperthermia, rhabdomyolysis, acute kidney injury.

checked by claude-sonnet-4-6 · May 8, 2026

comparative pharmacology7 claims4verified3inconclusive
verifiedThe critical difference is pharmacokinetic: α-PiHP reaches approximately 40% lower peak concentrations in blood and brain than α-PVP at equivalent doses in mice, yielding a four-fold higher locomotor ED₅₀ (4.0 vs. 1.1 mg/kg)[4]model confidence 99%
Verified

All values directly confirmed: ~40% lower Cmax, ED50 4.0 vs 1.1 mg/kg.

ED50 for locomotor activity: α-PiHP 4.0 mg/kg vs α-PVP 1.1 mg/kg (mice). α-PiHP reached ~40% lower Cmax in blood and brain.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn the De la Rosa 2025 observational study, intranasal α-PiHP (15–25 mg) produced a stimulant profile broadly similar to intranasal cocaine (75–90 mg), with two notable differences: blood pressure elevation was more sustained with α-PiHP, and the dose required for subjectively comparable effects was substantially lower by weight[9]model confidence 88%
Verified

More sustained BP elevation is confirmed. The dose comparison (15-25 mg vs 75-90 mg) clearly shows lower weight dose. 'Broadly similar stimulant profile' is a reasonable inference from this within-subjects comparison study.

More sustained blood pressure elevation than cocaine. α-PHiP 15-25 mg intranasal vs cocaine 75-90 mg intranasal.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedIn vitro DAT inhibitory potency is equivalent between the two compounds[4]model confidence 99%
Verified

Directly confirmed.

potency equivalent to α-PVP for DAT

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveα-PiHP and α-PHP are positional isomers sharing the molecular formula C₁₆H₂₃NO[1]model confidence 55%
Inconclusive

The review covers physicochemical properties of both compounds, so the molecular formula would be in the full text. The abstract does not confirm C₁₆H₂₃NO specifically.

Review of α-PHP and α-PiHP: legislative, physicochemical, toxicological, and analytical aspects.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveTheir analytical near-identity creates significant forensic challenges: standard color reagent tests cannot distinguish them, and differentiation requires GC-MS, LC-MS/MS, or NMR[15]model confidence 50%
Inconclusive

The paper is designed for distinguishing α-PiHP from α-PHP analytically, implying challenges exist. However, the specific failure of color reagent tests and the specific methods required (GC-MS, LC-MS/MS, NMR) are not mentioned in the abstract.

A dual strategy for differentiating alpha-pyrrolidinohexiophenone (α-PHP) and alpha-pyrrolidinoisohexanophenone (α-PiHP) in urine analysis.

checked by claude-sonnet-4-6 · May 8, 2026

verifiedDrug checking services have identified mislabeled samples containing unexpected pyrovalerone cathinones, underscoring the practical importance of this distinction.[23]model confidence 92%
Verified

The abstract confirms 4F-α-PiHP was identified at the Australian drug checking service CanTEST — an unexpected NPS found through drug checking, directly supporting this claim.

4F-α-PiHP identified at Australian drug checking service CanTEST.

checked by claude-sonnet-4-6 · May 8, 2026

inconclusiveIts DAT/SERT selectivity ratio places it in the high-reinforcement category alongside α-PVP and MDPV and distinguishes it from dual-mechanism cathinones like mephedrone.[7]model confidence 50%
Inconclusive

The DAT/SERT ratio data is confirmed for Me-analogs, but the comparative categorization against α-PVP, MDPV, and mephedrone specifically is not addressed in this abstract.

DAT/SERT ratio surpassed cocaine by >40-fold.

checked by claude-sonnet-4-6 · May 8, 2026

legal status1 claim1verified
verifiedα-PiHP is internationally controlled under Schedule II of the 1971 United Nations Convention on Psychotropic Substances, effective March 2023, following the recommendation of the WHO Expert Committee on Drug Dependence at its 45th meeting[1]model confidence 88%
Verified

March 2023 Schedule II placement is directly confirmed. The specific ECDD meeting number and Convention reference are not in the abstract but are not contradicted by a review paper explicitly covering legislative status.

Scheduled II under international control in March 2023.

checked by claude-sonnet-4-6 · May 8, 2026

05

Coverage & Gaps

effect links
56 links · 56 approved · 0 audited0/56 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 8, 2026

StepSourceQueryResults
1database lookupPubChemalpha-Pyrrolidinoisohexanophenone1 result, 1 selected
selection rationale

Primary chemical identity verification for α-PiHP

2literature searchPubMedalpha-PiHP pyrrolidinoisohexanophenone cathinone8 results, 8 selected
selection rationale

All directly relevant to α-PiHP pharmacology, toxicology, metabolism, and forensic analysis

3literature searchOpenAlexalpha-PiHP pyrrolidinoisohexanophenone novel psychoactive substance11 results, 7 selected
selection rationale

High-relevance papers not captured in PubMed search, citation-sorted to find landmark works

4literature searchPubMedalpha-PiHP dopamine transporter reuptake inhibition pharmacology1 result, 1 selected
selection rationale

Already catalogued

5literature searchPubMedalpha-PiHP toxicology fatality death cathinone2 results, 2 selected
selection rationale

Key postmortem concentration data for α-PiHP fatalities

6literature searchPubMedpyrovalerone cathinone dopamine norepinephrine serotonin transporter binding IC501 result, 1 selected
selection rationale

Key pharmacological binding data for pyrovalerone class including α-PiHP analogs

7literature searchOpenAlexpyrovalerone cathinone alpha-PVP alpha-PHP pharmacology dopamine transporter abuse10 results, 3 selected
selection rationale

High-citation review papers providing class-level context for α-PiHP

8clinical trial searchClinicalTrials.govalpha-PiHP pyrrolidinoisohexanophenone cathinone0 results
selection rationale

Confirms absence of clinical trials

9web searchWebSearchalpha-PiHP legal status DEA scheduling United States controlled substance9 results, 1 selected
selection rationale

Primary legal status for US

10web searchWebSearchalpha-PiHP EMCDDA early warning system scheduling UN convention 20239 results, 2 selected
selection rationale

EU scheduling and international control documentation

11web searchWebSearchalpha-PiHP UK legal status Misuse of Drugs Act controlled substance UK10 results, 2 selected
selection rationale

UK legal status

12document retrievalWebFetch—1 result, 1 selected
selection rationale

UK specific prevalence and legal data

13web searchWebSearchalpha-PiHP Australia Canada scheduling controlled substance legal analog10 results, 2 selected
selection rationale

International legal status

14document retrievalWebFetch—1 result, 1 selected
selection rationale

Chemical identity and scheduling verification

15web searchWebSearchWHO expert committee drug dependence alpha-PiHP critical review 2022 schedule II psychotropic9 results, 1 selected
selection rationale

Primary WHO pharmacological assessment and scheduling basis

16document retrievalWebFetch—1 result, 1 selected
selection rationale

User-reported dose/duration data; flagged as unverified, for editorial review

17literature searchOpenAlexalpha-PiHP pyrrolidinoisohexanophenone intoxication case report overdose4 results, 1 selected
selection rationale

New case report not found in PubMed search

18web searchWebSearchalpha-PiHP routes administration snorting vaping smoking intravenous user reports dose10 results, 2 selected
selection rationale

Critical human pharmacology paper and dose/ROA data

19document retrievalWebFetch—1 result, 1 selected
selection rationale

First human pharmacokinetic data for α-PiHP

20document retrievalWebFetch—1 result, 1 selected
selection rationale

Official WHO assessment data for α-PiHP

21literature searchPubMedalpha-PVP acute pharmacological effects humans observational naturalistic study2 results, 2 selected
selection rationale

Human observational data for α-PiHP and close analog α-PVP

22cross referenceCrossref/DOIverify_doi for key citations5 results, 1 selected
selection rationale

DOI verification for most-cited α-PiHP-specific papers

23data extractionPubMed/OpenAlex/WebSearch synthesisFinal data extraction and synthesis for research output31 results, 1 selected
selection rationale

Comprehensive synthesis for generation agent handoff

Research document (raw, unedited pipeline output)
# Research Output: α-PiHP

## Chemical Identity

**Verified data (PubChem CID 59809191 [Ref 22]; cross-confirmed with UNODC [Ref 22]):**

| Property | Value |
|---|---|
| Preferred IUPAC name | 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one |
| Common name | α-pyrrolidinoisohexanophenone (α-PiHP, α-PHiP) |
| Molecular formula | C₁₆H₂₃NO |
| Molecular weight | 245.36 g/mol |
| SMILES | CC(C)CC(N1CCCC1)C(C2=CC=CC=C2)=O |
| InChIKey | UOZWZANRCOALQL-UHFFFAOYSA-N |
| PubChem CID | 59809191 |
| Physical appearance | Off-white to white crystalline solid or powder [Ref 30] |

**Notes on seed data:** The brief's SMILES, formula, molecular weight, and InChIKey fields were all blank. All have now been verified from PubChem and UNODC sources and are consistent across both. No discrepancies identified.

**Structural context:** α-PiHP is a pyrovalerone-type substituted cathinone and a positional isomer of α-pyrrolidinohexanophenone (α-PHP). It differs from α-PHP only in the position of the methyl branch in the aliphatic side chain (isobutyl rather than n-butyl) (Dinis et al. 2024 [Ref 5]). It is structurally related to α-PVP (α-pyrrolidinovalerophenone), differing by one additional carbon in the chain. It belongs to the phenethylamine/cathinone scaffold with an N-pyrrolidine ring.

**Stereochemistry:** α-PiHP contains a chiral center at the α-carbon. Published literature does not specify which enantiomer predominates on the market or which is pharmacologically more active. No enantioselective pharmacology studies for α-PiHP were identified in this search. Market samples are presumed to be racemic. ⚠️ **FLAG: No published enantioselective data found — generation agent should note this gap explicitly.**

---

## Pharmacology

### Mechanism of Action

α-PiHP is a highly potent and selective monoamine reuptake inhibitor acting primarily at the dopamine transporter (DAT) and norepinephrine transporter (NET). It does not induce monoamine efflux — i.e., it is a reuptake inhibitor, not a releaser — a pharmacological property shared across the pyrovalerone class (Kolaczynska et al. 2021 [Ref 10]).

**DAT/NET inhibition:** Baarset et al. (2025 [Ref 1]) demonstrated in vitro that α-PiHP is a highly potent DAT and NET inhibitor, with potency equivalent to α-PVP at the DAT and slightly lower at the NET. In vivo locomotor studies in mice showed an ED₅₀ of 4.0 mg/kg for α-PiHP vs. 1.1 mg/kg for α-PVP — a fourfold difference attributable to α-PiHP reaching approximately 40% lower peak concentrations (C_max) in blood and brain, suggesting comparable intrinsic target potency but reduced CNS penetration relative to α-PVP [Ref 1].

**WHO ECDD assessment:** The WHO Expert Committee on Drug Dependence (45th meeting, October 2022) evaluated α-PiHP and reported that laboratory studies show it "can inhibit the uptake of dopamine and norepinephrine more potently than substances with known abuse potential, including methcathinone, cocaine and methamphetamine." Animal studies demonstrated "psychomotor stimulant effects comparable to cocaine and methamphetamine" (WHO ECDD 2022 [Ref 25]).

**SERT activity:** Pyrovalerone cathinones as a class exhibit no meaningful SERT inhibition at concentrations below 10 μM (Kolaczynska et al. 2021 [Ref 10]). No α-PiHP-specific SERT binding data were identified. The high DAT/SERT selectivity ratio documented for methyl-substituted α-PiHP analogs (>40-fold above cocaine by this metric; Gréen et al. 2025 [Ref 15]) is consistent with negligible serotonergic activity in the parent compound.

**DAT/SERT selectivity and abuse liability:** High DAT/SERT selectivity is associated with strong reinforcing effects and correspondingly high abuse liability (Gréen et al. 2025 [Ref 15]; Brueckner et al. 2024 [Ref 13]).

**Specific binding constants (IC₅₀):** No paper reporting a direct IC₅₀ value for α-PiHP at human DAT or NET was identified. Baarset 2025 [Ref 1] characterizes relative potency compared to α-PVP without absolute IC₅₀ values. Kolaczynska 2021 [Ref 10] provides pyrovalerone class IC₅₀ ranges (0.02–8.7 μM at DAT; 0.03–4.6 μM at NET) but does not specifically test α-PiHP. ⚠️ **FLAG: No α-PiHP-specific IC₅₀ values at DAT or NET found in any published source. Generation agent must not fabricate specific numerical binding values.**

### Human Pharmacokinetics

**De la Rosa et al. (2025 [Ref 28]) — first human PK/PD study:** A naturalistic observational study in 17 healthy adults with prior psychostimulant experience administered α-PHiP intranasally at 15–25 mg, with cocaine (75–90 mg intranasal) as comparator. Key findings:

- **T_max:** ~20 minutes (measured in oral fluid)
- **Half-life:** ~1.1 hours
- **Urinary excretion unchanged:** <1% (extensive first-pass metabolism)
- **Matrices sampled:** oral fluid, urine, sweat, dried blood spots
- **Interindividual variability:** High across all matrices
- **Subjective profile:** Similar to cocaine; effects peaked within the first hour
- **Cardiovascular:** Heart rate increases; blood pressure elevation more sustained than cocaine

**⚠️ FLAG: This is a naturalistic observational study in experienced users, not a controlled clinical trial. Doses reflect self-selected recreational ranges, not a dose-finding protocol. Generalizability limited.**

### In Vivo / Forensic Pharmacokinetics

Blood and plasma concentrations documented across clinical and postmortem cases:

- **Postmortem blood (intoxication and fatal):** 0.3–840 ng/mL, with wide range overlapping between intoxication and fatality contexts (Gomonit et al. 2026 [Ref 2])
- **Postmortem urine:** up to 2,600 ng/mL (Gomonit et al. 2026 [Ref 2])
- **Postmortem vitreous humor:** 350 ng/mL (Gomonit et al. 2026 [Ref 2])
- **Postmortem liver:** 88 ng/g (Gomonit et al. 2026 [Ref 2])
- **Living forensic plasma (German cases, n=8):** 7.33–118 μg/L (mean 44.7, median 33.7 μg/L) (Brueckner et al. 2024 [Ref 13])
- **Fatal poisonings, Finland (n cases with α-PiHP):** Median femoral blood 0.14 mg/L (range 0.03–2.1 mg/L) (Kriikku & Ojanperä 2024 [Ref 9])
- **Fatal coal miner case (α-PiHP + tramadol):** Blood 0.062 μg/mL; urine 0.163 μg/mL (Skowronek et al. 2025 [Ref 26])

⚠️ **FLAG: Substantial overlap between intoxication and fatal blood concentrations documented by Gomonit 2026 [Ref 2]. No validated therapeutic index or LD₅₀ available. These values should not be used as safe/unsafe thresholds.**

### Metabolism

**Human urinary metabolites (Kemenes et al. 2023 [Ref 7]):** Ten in vivo urinary metabolites identified in Hungarian users (8 Phase I, 2 Phase II). Five metabolites were more abundant in urine than the parent compound:

- **M01** (major): β-ketone reduction
- **M06** (major): pyrrolidine ring oxidation + aliphatic hydroxylation + ketone reduction (combined)
- **M04**: ketone reduction + aliphatic hydroxylation
- **M07**: glucuronidation of ketone-reduced metabolite (Phase II)
- **M09**: ring-opening followed by carboxylation

**In vitro HLM metabolism (Yeh et al. 2024 [Ref 4]):** After 5 hours incubation with pooled human liver microsomes, 64.7% of α-PiHP remained unmetabolized. Nine Phase I metabolites identified; primary pathways are β-ketone reduction (M1) and aliphatic hydroxylation (M2). The aliphatic hydroxylation metabolite (M2) peak count and retention time were identified as markers for distinguishing α-PiHP from α-PHP in urine.

**Primary metabolite in postmortem cases:** OH-α-PiHP (4-hydroxy-α-PiHP) co-detected with parent in all postmortem tissues in the Wachholz 2023 case [Ref 6].

**CYP enzymes:** No specific CYP isoform identification for α-PiHP has been published. ⚠️ **FLAG: CYP enzyme involvement is a gap; class-level inference only (pyrovalerone cathinones generally metabolized via CYP3A4/CYP2C19 based on structural analogy).**

---

## History

**First synthesis:** The date and originator of α-PiHP synthesis are undocumented in the published scientific literature. The compound appears to have emerged from clandestine synthesis as a structural variant of α-PHP, likely designed to exploit regulatory gaps as predecessor compounds were scheduled.

**First market detection:** α-PiHP was first identified in China in 2016 (Dinis et al. 2024 [Ref 5]). It was first formally reported to the EMCDDA Early Warning System from Slovenia in December 2016 (Kemenes et al. 2023 [Ref 7]). Hungary independently reported it in August 2016 but it remained rare until 2021, when consumption became widespread there [Ref 7].

**First forensic case with biological concentrations:** Adamowicz et al. (2020 [Ref 8]) — first reported intoxication case with quantified concentrations in biological specimens.

**First fatal case:** Wachholz et al. (2023 [Ref 6]) published the first confirmed fatality primarily attributable to α-PiHP, including comprehensive postmortem tissue distribution data and the first identification of OH-α-PiHP in postmortem specimens.

**Market trajectory:** α-PiHP emerged as a substitute for α-PHP, itself a replacement for α-PVP/MDPV as regulations caught up (Kuropka et al. 2022 [Ref 11]). By 2022 it was among the top five synthetic cathinones seized by weight across Europe (Baarset et al. 2025 [Ref 1]).

**UK (monkey dust):** α-PiHP has been identified as a component of "monkey dust" (mixed pyrovalerone street preparations) in North Staffordshire, UK (ACMD 2025 [Ref 24]).

**Taiwan:** Widespread use documented; the forensic need to distinguish α-PiHP from α-PHP in urine drove development of analytical methods in Taiwan (Yeh et al. 2024 [Ref 4]).

**Regulatory/scheduling timeline:**

| Date | Event |
|---|---|
| August 2016 | First reported in Hungary (Kemenes 2023 [Ref 7]) |
| December 2016 | First formal EMCDDA Early Warning System notification (from Slovenia) [Ref 7] |
| 2016 | First detected in China; controlled there [Ref 5] |
| 2019 | First intoxication case with biological specimen concentrations (Adamowicz 2020 [Ref 8]) |
| October 2022 | WHO ECDD 45th meeting recommends Schedule II of 1971 Convention [Ref 25] |
| March 9, 2023 | EU Council Decision (EU) 2023/567 — α-PiHP subjected to control measures |
| March 2023 | UN Schedule II of 1971 Convention on Psychotropic Substances [Ref 5, 22] |
| December 13, 2023 | US DEA specific Schedule I listing established (code 7551) [Ref 23] |

---

## Subjective Effects

**Data sources:** No randomized controlled human trials of α-PiHP exist. Subjective effect data derives from: (1) the De la Rosa 2025 observational study [Ref 28]; (2) intoxication case reports; (3) forensic behavioral documentation; (4) class-level literature on α-PVP/α-PHP. All effects below should be labeled by evidence source in the generated article.

**Human observational study (De la Rosa et al. 2025 [Ref 28]):** In 17 participants administered 15–25 mg intranasally, α-PiHP produced a stimulant profile broadly similar to cocaine (75–90 mg intranasal). Effects peaked within the first hour. Cardiovascular effects included heart rate increases and more sustained blood pressure elevation than cocaine.

**Effects documented in intoxication case reports and forensic literature (Dinis 2024 [Ref 5]; Brueckner 2024 [Ref 13]; ECDD repository [Ref 30]):**
- Psychomotor agitation, extreme restlessness
- Aggressive behavior; forensic cases frequently involved violent crimes (Brueckner 2024 [Ref 13])
- Overstimulation (intense, described as similar in character to α-PVP/α-PHP)
- Hallucinations, delusions, psychosis (at higher doses and in overdose)
- Insomnia, appetite suppression/anorexia
- Nausea, photophobia, trismus
- Anxiety, paranoia (documented for class; Daziani 2023 [Ref 17])

**Effect taxonomy mapping (evidence basis noted):**
- *Stimulation, wakefulness* — documented
- *Appetite suppression* — documented
- *Euphoria* — class-level/mechanism-based; directly implied by DAT inhibition
- *Motivation enhancement, focus enhancement* — class-level/low-dose inference
- *Thought acceleration* — class-level inference
- *Compulsive redosing urge* — class mechanism (DAT)
- *Anxiety, paranoia* — documented in cases and class literature
- *Agitation, restlessness* — documented in forensic cases
- *Auditory hallucinations, external hallucinations, delusions, delirium* — documented at overdose doses
- *Heart rate perception changes, vasoconstriction* — documented
- *Temperature dysregulation, excessive sweating* — documented in case reports
- *Pupil dilation* — class inference (sympathomimetic)
- *Muscle tension, bruxism* — class inference

⚠️ **FLAG: Most effect data conflates recreational and overdose doses. No dose-stratified psychometric studies exist. Generation agent should clearly distinguish recreational-dose effects from overdose presentations.**

### Duration Data

**Intranasal (De la Rosa 2025 [Ref 28], human observational):**
- Onset: ~20 minutes to peak (T_max in oral fluid)
- Half-life: ~1.1 hours
- Primary effect duration: approximately 2–4 hours (PK-derived estimate)

**Smoked (PsychonautWiki [Ref 27] — unverified, page not fully approved):**
- Onset: ~1 minute
- Total duration: 1–3 hours
- After-effects: 6–12 hours

**Oral route delay:** Dinis 2024 [Ref 5] notes that oral α-PiHP onset is substantially delayed (30–60 minutes) compared to intranasal/inhaled routes (2–20 minutes for α-PHP/α-PVP), creating specific overdose risk from inadvertent redosing before effects manifest.

---

## Safety & Toxicity

### Acute Toxicity and Fatal Cases

**Fatal cases documented in the literature:**

1. **Wachholz et al. 2023 [Ref 6]:** First confirmed α-PiHP fatality accepted as cause of death following autopsy, histopathology, and toxicology. Comprehensive postmortem distribution documented across all major organs, blood compartments, vitreous humor, CSF, and adipose tissue.

2. **Skowronek et al. 2025 [Ref 26]:** 40-year-old coal miner; sudden cardiac arrest. α-PiHP: blood 0.062 μg/mL, urine 0.163 μg/mL; metabolite OH-α-PiHP: blood 0.080 μg/mL, urine 1.50 μg/mL. Tramadol at toxic blood concentration (1.60 μg/mL). Multi-drug fatality in occupational setting.

3. **Kriikku & Ojanperä 2024 [Ref 9]:** Finnish postmortem series 2018–2023; 136 SC findings in 118 deaths; α-PiHP implicated among these cases. Median femoral blood α-PiHP in fatal poisonings: 0.14 mg/L (range 0.03–2.1 mg/L). 82% male, median age 35. Concomitant opioids, stimulants, or sedatives in 69–92% of cases.

4. **Gomonit et al. 2026 [Ref 2]:** US forensic case series; wide concentration range (0.3–840 ng/mL postmortem blood) with considerable overlap between intoxication and fatal exposures. MDPiHP also identified independently in one case.

**Non-fatal severe intoxication:**
- **T'kind et al. 2024 [Ref 3]:** 32-year-old male ingested 5 grams (suicide attempt). Severe hyperthermia, rhabdomyolysis, acute kidney injury. Managed with dantrolene (prompt temperature reduction). Diagnostic uncertainty between serotonin syndrome and sympathomimetic toxidrome.

**LD₅₀:** No published LD₅₀ data for α-PiHP in any species. ⚠️ **FLAG: Safety-critical value absent — generation agent must not assign an LD₅₀.**

**Concentration interpretation difficulty:** Wide overlap between intoxication and fatal blood concentrations (Gomonit 2026 [Ref 2]). Individual tolerance, route, body mass, temperature, and poly-drug use substantially modulate outcome. Blood concentration alone is insufficient to assess lethality risk.

### Organ/System Toxicity

**Cardiovascular:**
- Tachycardia, hypertension (De la Rosa 2025 [Ref 28]; case reports throughout)
- Blood pressure elevation more sustained than cocaine (De la Rosa 2025 [Ref 28])
- Cardiac arrhythmias (documented for cathinone class; Dinis 2024 [Ref 5])
- Sudden cardiac arrest (Skowronek 2025 [Ref 26]; Kriikku 2024 [Ref 9])

**Thermoregulatory:**
- Hyperthermia — potentially life-threatening (T'kind et al. 2024 [Ref 3])
- Consistent with sympathomimetic toxidrome

**Neuromuscular / Renal:**
- Rhabdomyolysis (T'kind 2024 [Ref 3])
- Acute kidney injury (secondary to rhabdomyolysis) (T'kind 2024 [Ref 3])
- Psychomotor agitation (ubiquitous in intoxication cases)
- Seizures (documented at class level; implied in coal miner case [Ref 26])

**Psychiatric:**
- Hallucinations, delusions, psychosis (high dose / overdose) [Ref 5, 30]
- Excited/agitated delirium syndrome (documented for pyrovalerone class; Penders et al. 2012 [Ref 31])

### Toxidrome Classification

Presentations consistent with **sympathomimetic toxidrome** (tachycardia, hypertension, hyperthermia, agitation, diaphoresis). Documented diagnostic uncertainty with **serotonin syndrome** (T'kind 2024 [Ref 3]). Key differentiating features: clonus, hyperreflexia, ocular clonus more specific to serotonin syndrome; pyrovalerone cathinones have minimal SERT activity, making serotonin syndrome less mechanistically plausible but not excludable at very high doses or with co-ingestions.

### Clinical Management (from case literature)

- **Dantrolene:** Successfully used for life-threatening hyperthermia in one case when cyproheptadine was unavailable (T'kind 2024 [Ref 3]); acts by blocking skeletal muscle calcium release
- **Supportive care:** Standard sympathomimetic management (cooling, IV fluids, benzodiazepines for agitation) — inferred from class; no α-PiHP-specific protocol published (Paillet-Loilier 2014 [Ref 19])
- **No specific antidote** exists (Paillet-Loilier 2014 [Ref 19])

### Polydrug Patterns

Most fatal and severe cases involve poly-drug use. Kriikku & Ojanperä 2024 [Ref 9] found concomitant opioids, stimulants, or sedatives in 69–92% of SC-related death cases; only 1.7% had synthetic cathinones as the sole drug. Most common co-detections: opioids, benzodiazepines, pregabalin, alcohol, amphetamines [Ref 9, 13, 15, 26].

---

## Harm Reduction

### Routes of Administration and Risk Profile

Documented ROAs from intoxication literature (Dinis 2024 [Ref 5]; De la Rosa 2025 [Ref 28]):

| Route | Evidence | Notes |
|---|---|---|
| Intranasal (insufflation) | Human study [Ref 28] | Most common recreational route; 15–25 mg studied |
| Inhalation / vaporization | Case reports [Ref 5] | Rapid onset (~1 min); highest peak concentrations; "foiling" documented |
| Oral | Case reports [Ref 5] | Delayed onset (30–60 min); redosing-before-onset overdose risk |
| Intravenous | Case reports [Ref 5] | Highest bioavailability; highest risk |
| Rectal | Case reports [Ref 5] | Documented |

### Key Risk Factors

1. **Polydrug use:** Combination with opioids or CNS depressants (benzodiazepines, pregabalin, alcohol) accounts for the majority of fatal and severe intoxication cases [Ref 9, 13, 26]. This combination is contraindicated.

2. **Hyperthermia:** Temperature dysregulation is a documented life-threatening acute risk. Hot environments (clubs, raves) substantially increase risk. Cooling and monitoring are critical.

3. **Compulsive redosing:** The DAT inhibition mechanism and class-level behavioral evidence indicate high compulsive redosing potential, escalating cumulative dose and toxicity risk.

4. **Oral route overdose risk:** The substantially delayed onset with oral administration creates a specific scenario where users may redose believing the first dose was insufficient, leading to inadvertent overdose [Ref 5].

5. **Product authenticity:** α-PiHP cannot reliably be identified from α-PHP or other pyrovalerone cathinones by color reagent testing alone (structural similarity). GC-MS, LC-MS, or NMR required for definitive identification. Drug checking services have identified mislabeled samples containing unexpected pyrovalerone cathinones (Algar et al. 2024 [Ref 12]).

6. **Emergency recognition:** Both sympathomimetic toxidrome and potential serotonin syndrome should be considered in emergency presentations; dantrolene may be appropriate for refractory hyperthermia (T'kind 2024 [Ref 3]).

---

## Tolerance & Dependence

**No α-PiHP-specific tolerance or dependence studies exist.** All content in this section is class-level inference from related pyrovalerone cathinones (α-PVP, MDPV).

**Abuse potential:** The WHO ECDD assessed α-PiHP as having high abuse potential based on animal models and pharmacological profile showing stimulant effects comparable to cocaine and methamphetamine [Ref 25].

**Class-level dependence evidence:** Weinstein et al. 2017 [Ref 32] and Daziani et al. 2023 [Ref 17] document that chronic synthetic cathinone use can produce:
- Rapid tolerance development with binge use
- Compulsive redosing patterns driven by dopaminergic reward
- Psychological dependence with cravings
- No well-characterized physical withdrawal syndrome (distinct from opioids/benzodiazepines)
- Possible post-acute psychological sequelae (anxiety, depression, anhedonia) — class-level inference

**Mechanism:** High, selective DAT inhibition combined with lack of SERT activity is associated with high reinforcing efficacy and abuse potential (Gréen et al. 2025 [Ref 15]).

⚠️ **FLAG: All tolerance and dependence content is class-level inference. Generation agent should clearly label all dependence claims as extrapolated from related compounds, not α-PiHP-specific data.**

---

## Interactions

No controlled drug interaction studies specific to α-PiHP exist. The following summarizes documented co-exposure patterns and mechanism-based interactions:

| Interaction | Mechanism/Evidence | Source | Risk Level |
|---|---|---|---|
| Opioids | Synergistic CNS depression; cardiac stress may continue while sedation masks decline | Case series [Ref 9, 26] | **High** (documented in fatal cases) |
| Tramadol | Tramadol: monoamine reuptake inhibition + seizure threshold reduction; cardiac arrest documented with co-use | Fatal case [Ref 26] | **High** |
| Benzodiazepines | Common co-use; may mask escalating intoxication; lethargic outcomes documented | Case series [Ref 13, 9] | Moderate–High |
| Pregabalin | Additive CNS depression; co-detected in intoxication cases | Case series [Ref 13] | Moderate |
| MAO inhibitors | Hypertensive crisis and serotonin-like syndrome risk via excessive monoamine accumulation | Mechanism only; no published cases | **High** (class-level contraindication) |
| Other cathinones/stimulants | Additive cardiovascular load; multi-pyrrolidinophenone use frequently documented | Case series [Ref 13, 2] | Moderate–High |
| Alcohol | Pharmacodynamic interaction; co-detected in death series | Case series [Ref 9] | Moderate |

⚠️ **FLAG: All interaction severity ratings are based on co-occurrence data or mechanistic inference, not controlled interaction studies. All interaction severity scores in the database require editorial assignment and should be reviewed by an editor before publication.**

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Effective Date | Source |
|---|---|---|---|---|
| United Nations | Controlled | Schedule II, 1971 Convention on Psychotropic Substances | March 2023 | [Ref 5, 22, 25] |
| United States | Schedule I | Controlled Substances Act; DEA Code 7551 | December 13, 2023 | [Ref 23] |
| European Union | Controlled | Council Decision (EU) 2023/567 | March 9, 2023 | Web-retrieved |
| United Kingdom | Class B | Misuse of Drugs Act 1971 (generic cathinone structural definition) | 2010 (generic definition); confirmed in force | [Ref 24] |
| Australia | Controlled | Office of Drug Control; listed controlled substance | Confirmed 2024 | Web search |
| Canada | Controlled (analog provision) | Controlled Drugs and Substances Act | Case-by-case analog assessment | Web search |
| China | Controlled | First detected and scheduled in China | 2016 | [Ref 5] |

**US history:** Prior to December 2023, α-PiHP was implicitly controlled under the US CSA as a positional isomer of α-PHP (itself Schedule I). The December 2023 Federal Register entry (Document 2023-27292) established a specific separate listing with DEA code 7551 [Ref 23].

**UK note:** The ACMD 2025 harms assessment [Ref 24] recorded 125 forensic seizure detections of α-PiHP in the UK (2020–2023), with 0 emergency department presentations and 0 postmortem findings in that period — a lower harm profile than α-PHP and MDPHP in the UK context.

**EU:** Detected in 18 EU Member States and controlled in at least 7 before the Union-wide Council Decision (Dinis 2024 [Ref 5]).

---

## Clinical Trials

No clinical trials for α-PiHP were identified on ClinicalTrials.gov. This is consistent with its status as a substance with no identified therapeutic utility, as confirmed by WHO ECDD [Ref 25].

---

## Community Feedback Analysis

No community feedback submitted (Part A2 of the brief was empty).

---

## Gaps & Flags

### Critical Gaps (generation agent must note these explicitly)

1. **No substance-specific IC₅₀ values at DAT or NET.** Pharmacology section relies on comparative potency statements (equivalent to α-PVP at DAT) and class-level IC₅₀ ranges. Specific numerical binding values must not be fabricated.

2. **No LD₅₀ data.** No published lethal dose estimates for α-PiHP in any species. Safety-critical value entirely absent.

3. **No enantioselective pharmacology.** Market material presumed racemic; no enantiomer-specific activity data available.

4. **No CYP enzyme identification.** CYP isoform involvement in α-PiHP metabolism has not been published. Class-level inference (CYP3A4/2C19) may be stated as inference only.

5. **No systematic dependence/withdrawal characterization.** All dependence and tolerance data are class-level inferences from α-PVP and MDPV literature.

6. **Oral dose range absent.** No published controlled or observational dose data for oral administration specifically.

### Dose/Duration Proposals for Editorial Review

Evidence hierarchy applied (existing DB values → community consensus → structural analog inference):

- **Intranasal:** 15–25 mg (human observational study; De la Rosa 2025 [Ref 28]) — only route with any controlled human exposure data; represents "common" recreational range.
- **Smoked (user reports, unverified; PsychonautWiki [Ref 27]):** Threshold <3 mg, light 3–10 mg, common 10–20 mg, strong 20–30 mg, heavy >30 mg.
- **Duration intranasal (PK-derived):** Onset ~20 min; primary effects ~2–4 hours (half-life ~1.1 h); after-effects unclear.
- **Duration smoked (user reports [Ref 27]):** Onset ~1 min; total ~1–3 hours; after-effects 6–12 hours.

⚠️ All dose and duration proposals require editorial review before database entry.

### Contradictions

- The Dinis 2024 review [Ref 5] states oral onset is 30–60 min for α-PiHP vs. 2–20 min for α-PHP/α-PVP but cites no primary source for this. Treat as provisional.

### Sections Relying on Structural Analogy / Class Inference

- CYP enzyme involvement
- Tolerance and dependence characteristics
- Drug interactions (all except opioids and tramadol, which have case-level evidence)
- SERT activity quantification
- MAO inhibitor interaction
- Withdrawal syndrome characterization

### Safety-Critical Values Not Confirmed by Published Sources

- LD₅₀: Not available in any species
- Therapeutic index: Not calculable (no LD₅₀)
- Minimum lethal dose: Not established (wide overlap between intoxication and fatal blood concentrations)
- All drug interaction severity grades: Require editorial assignment; none are from controlled studies